Information on EC 3.5.1.99 - fatty acid amide hydrolase

New: Word Map on EC 3.5.1.99
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Mark a special word or phrase in this record:
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)


The expected taxonomic range for this enzyme is: Eukaryota

EC NUMBER
COMMENTARY
3.5.1.99
-
RECOMMENDED NAME
GeneOntology No.
fatty acid amide hydrolase
-
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
anandamide + H2O = arachidonic acid + ethanolamine
show the reaction diagram
-
-
-
-
anandamide + H2O = arachidonic acid + ethanolamine
show the reaction diagram
structure-function relationship and catalytic mechanism, overview
P97612
oleamide + H2O = oleic acid + NH3
show the reaction diagram
-
-
-
-
oleamide + H2O = oleic acid + NH3
show the reaction diagram
structure-function relationship and catalytic mechanism, overview
P97612
PATHWAY
BRENDA Link
KEGG Link
MetaCyc Link
anandamide degradation
-
-
SYSTEMATIC NAME
IUBMB Comments
fatty acylamide amidohydrolase
Integral membrane protein, the enzyme is responsible for the catabolism of neuromodulatory fatty acid amides, including anandamide and oleamide, occurs in mammalia.
CAS REGISTRY NUMBER
COMMENTARY
153301-19-0
-
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
recombinant
-
-
Manually annotated by BRENDA team
Male albino SwissWebster
-
-
Manually annotated by BRENDA team
male C57BL/6J mice
-
-
Manually annotated by BRENDA team
male C75BL/6J mice
-
-
Manually annotated by BRENDA team
Mus musculus C57BL/6J
-
-
-
Manually annotated by BRENDA team
adult male Wistar rats
-
-
Manually annotated by BRENDA team
recombinant
-
-
Manually annotated by BRENDA team
recombinant mutant L192F/F194Y/A377T/S435N/I491V/V495M, a humanized version of the rat FAAH
SwissProt
Manually annotated by BRENDA team
SpragueDawley
-
-
Manually annotated by BRENDA team
Rattus norvegicus Sprague-Dawley
female
-
-
Manually annotated by BRENDA team
Rattus norvegicus Sprague-Dawley
SpragueDawley
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
evolution
P97612
FAAH is a member of the amidase signature family found in bacteria, archaea and eukaryotes
evolution
-
fatty acid amide hydrolase is an amidase-signature family member
malfunction
-
effects of FAAH inhibition on bladder function during urodynamics in awake rats, overview
malfunction
-
genetic deletion of FAAH is associated with enhanced acute doxorubicin-induced myocardial cell death and decreased survival, mechanism of the doxorubicin-induced myocardial cell death in FAAH+/+ and FAAH-/- mice, overview
malfunction
-
tissue-specific changes in N-acyl ethanolamine congeners and N-acyl taurines metabolism caused by FAAH disruption in central and peripheral tissues, overview
malfunction
Rattus norvegicus Sprague-Dawley
-
effects of FAAH inhibition on bladder function during urodynamics in awake rats, overview
-
malfunction
Mus musculus C57BL/6J
-
genetic deletion of FAAH is associated with enhanced acute doxorubicin-induced myocardial cell death and decreased survival, mechanism of the doxorubicin-induced myocardial cell death in FAAH+/+ and FAAH-/- mice, overview
-
metabolism
-
FAAH is a key enzyme in the endocannabinoid metabolism
metabolism
-
fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury
physiological function
-
FAAH is a degradative enzyme for a group of endogenous signaling lipids that includes anandamide, that acts as an endocannabinoid and an endovanilloid by activating cannabinoid and vanilloid type 1 transient receptor potential,TRPV1, receptors, respectively, on dorsal root ganglion sensory neurons. Inhibition of FAAH activity increases anandamide concentrations in nervous tissue and reduces sensory hypersensitivity in animal pain models
physiological function
-
FAAH is the chief catabolic enzyme regulating the endogenous cannabinoid N-arachidonoylethanolamine, i.e. anandamide
physiological function
-
FAAH is the key hydrolytic enzyme for the endogenous cannabinoid receptor ligand anandamide
physiological function
-
genetic or pharmacological ablation of FAAH promotes analgesia and anxiolytic effects without disrupting motor coordination
physiological function
-
importance of FAAH in controlling endogenous anandamide levels in the brain and consequently the importance of FAAH as a regulatory enzyme for key physiological functions. FAAH is one of the main enzymes responsible for terminating the signaling of endocannabinoids in the brain, it has a role in neuropsychiatric disorders
physiological function
-
endocannabinoid-degrading enzyme fatty acid amide hydrolase. FAAH substrates in the urinary bladder act via local CB2-mediated signals
physiological function
P97612
fatty acid amide hydrolase degrades lipid signaling molecules such as the endogenous cannabinoids anandamide, i.e. N-arachidonyl ethanolamine, and the sleep-inducing substance oleamide, i.e. cis-9-octadecenamide
physiological function
-
fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury
physiological function
-
fatty acid amide hydrolase is the principal enzyme responsible for anandamide hydrolysis in mammalian tissues and regulates amidated lipid transmitters, including the endocannabinoid anandamide and its N-acyl ethanolamine congeners and transient receptor potential channel agonists N-acyl taurines, in a tissue-specific manner, overview
physiological function
Rattus norvegicus Sprague-Dawley
-
endocannabinoid-degrading enzyme fatty acid amide hydrolase. FAAH substrates in the urinary bladder act via local CB2-mediated signals
-
physiological function
Mus musculus C57BL/6J
-
fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury
-
metabolism
Mus musculus C57BL/6J
-
fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury
-
additional information
-
anandamide induces enhanced cell death in human cardiomyocytes pretreated by FAAH inhibitor, and enhances sensitivity to reactive oxygen species generation in inflammatory cells of FAAH knockouts
additional information
-
anandamide induces enhanced cell death in human cardiomyocytes pretreated by FAAH inhibitor, and enhances sensitivity to reactive oxygen species generation in inflammatory cells of FAAH knockouts, it triggers concentration-dependent respiratory burst (ROS generation) in neutrophil granulocytes isolated from FAAH+/+ mice
additional information
-
catalytic triad is formed by Ser241-Ser217-Lys142
additional information
Q7XJJ7
overexpression of fatty acid amide hydrolase induces early flowering in Arabidopsis thaliana. The FLOWERING LOCUST gene, which plays a major role in regulating flowering time, and one target MADS box transcription factor, SEPATALLA3 (SEP3), are elevated in AtFAAH overexpressors, that also show enhanced NAE hydrolase activity. The early flowering phenotype plants have lower endogenous N-acylethanolamines, NAE, levels in leaves compared to wild-type prior to flowering. The number of rosette leaves and rosette diameter is not affected by altered AtFAAH expression
additional information
-
the active site is located in the center cavity defined by an atypical Ser-Ser-Lys catalytic triad which comprises the catalytic nucleophile residue Ser241 along with residues Ser217 and Lys142
additional information
Mus musculus C57BL/6J
-
anandamide induces enhanced cell death in human cardiomyocytes pretreated by FAAH inhibitor, and enhances sensitivity to reactive oxygen species generation in inflammatory cells of FAAH knockouts, it triggers concentration-dependent respiratory burst (ROS generation) in neutrophil granulocytes isolated from FAAH+/+ mice
-
SUBSTRATE
PRODUCT                      
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
LITERATURE
(Substrate)
COMMENTARY
(Product)
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
(11Z)-eicosenamide + H2O
(11Z)-eicosenoic acid + NH3
show the reaction diagram
-
105% of the activity with oleamide
-
-
?
(12Z)-octadecenamide + H2O
(12Z)-octadecenoic acid + NH3
show the reaction diagram
-
92% of the activity with oleamide
-
-
?
(13Z)-eicosenamide + H2O
(13Z)-eicosenoic acid + NH3
show the reaction diagram
-
103% of the activity with oleamide
-
-
?
(13Z)-octadecenamide + H2O
(13Z)-octadecenoic acid + NH3
show the reaction diagram
-
82% of the activity with oleamide
-
-
?
(15Z)-octadecenamide + H2O
(15Z)-octadecenoic acid + NH3
show the reaction diagram
-
90% of the activity with oleamide
-
-
?
(5Z)-eicosenamide + H2O
(5Z)-eicosenoic acid + NH3
show the reaction diagram
-
116% of the activity with oleamide
-
-
?
(5Z,8Z,11Z,14Z)-N-(2-fluoroethyl)icosa-5,8,11,14-tetraenamide + H2O
?
show the reaction diagram
-
hydrolysis rate is 1.3fold higher than the rate of anandamide hydrolysis
-
-
?
(5Z,8Z,11Z,14Z)-N-(2-hydroxy-1,1-dimethylethyl)icosa-5,8,11,14-tetraenamide + H2O
?
show the reaction diagram
-
hydrolyzed at 4.3% the rate of anandamide
-
-
?
(5Z,8Z,11Z,14Z)-N-(2-methylpropyl)icosa-5,8,11,14-tetraenamide + H2O
?
show the reaction diagram
-
hydrolyzed at 2% the rate of anandamide
-
-
?
(5Z,8Z,11Z,14Z)-N-(3-hydroxyphenyl)icosa-5,8,11,14-tetraenamide + H2O
?
show the reaction diagram
-
hydrolysis rate is 1.5fold higher than the rate of anandamide hydrolysis
-
-
?
(5Z,8Z,11Z,14Z)-N-(4-hydroxyphenyl)icosa-5,8,11,14-tetraenamide + H2O
?
show the reaction diagram
-
hydrolyzed at 16% the rate of anandamide
-
-
?
(5Z,8Z,11Z,14Z)-N-tert-butylicosa-5,8,11,14-tetraenamide + H2O
?
show the reaction diagram
-
hydrolyzed at 1.8% the rate of anandamide
-
-
?
(5Z,8Z,11Z,14Z)-N-[(1S)-1-methylpropyl]icosa-5,8,11,14-tetraenamide + H2O
?
show the reaction diagram
-
hydrolyzed at 6.3% the rate of anandamide
-
-
?
(5Z,8Z,11Z,14Z)-N-[(2R)-2-hydroxypropyl]icosa-5,8,11,14-tetraenamide + H2O
?
show the reaction diagram
-
hydrolysis rate is 1.2fold higher than the rate of anandamide hydrolysis
-
-
?
(5Z,8Z,11Z,14Z)-N-[(2S)-2-hydroxypropyl]icosa-5,8,11,14-tetraenamide + H2O
?
show the reaction diagram
-
hydrolyzed at 21% the rate of anandamide
-
-
?
(6Z)-octadecenamide + H2O
(6Z)-octadecenoic acid + NH3
show the reaction diagram
-
91% of the activity with oleamide
-
-
?
(7Z)-octadecenamide + H2O
(7Z)-octadecenoic acid + NH3
show the reaction diagram
-
109% of the activity with oleamide
-
-
?
(8Z)-eicosenamide + H2O
(8Z)-eicosenoic acid + NH3
show the reaction diagram
-
112% of the activity with oleamide
-
-
?
(9E)-octadecenamide + H2O
(9E)-octadecenoic acid + NH3
show the reaction diagram
-
52% of the activity with oleamide
-
-
?
(9Z)-N-(2-hydroxyethyl)octadec-9-enamide + H2O
?
show the reaction diagram
-
hydrolyzed at 61% the rate of anandamide
-
-
?
(9Z,12Z)-N-(2-hydroxyethyl)octadeca-9,12-dienamide + H2O
?
show the reaction diagram
-
hydrolyzed at 75% the rate of anandamide
-
-
?
(9Z,12Z)-N-[(1R)-2-hydroxy-1-methylethyl]octadeca-9,12-dienamide + H2O
?
show the reaction diagram
-
hydrolyzed at 20.5% the rate of anandamide
-
-
?
(R)-alpha-methanandamide + H2O
?
show the reaction diagram
-
2.4% of the activity with anandamide
-
-
?
(R)-beta-methanandamide + H2O
?
show the reaction diagram
-
121% of the activity with anandamide
-
-
?
(S)-alpha-methanandamide + H2O
?
show the reaction diagram
-
23% of the activity with anandamide
-
-
?
(S)-beta-methanandamide + H2O
?
show the reaction diagram
-
21% of the activity with anandamide
-
-
?
1-arachidonoylglycerol + H2O
?
show the reaction diagram
-
-
-
-
?
11,14,17-eicosatrienamide + H2O
11,14,17-eicosatrienoic acid + NH3
show the reaction diagram
-
140% of the activity with oleamide
-
-
?
11,14-eicosadienamide + H2O
? + NH3
show the reaction diagram
-
127% of the activity with oleamide
-
-
?
2,2-dimethyloleamide + H2O
2,2-dimethyloleic acid + NH3
show the reaction diagram
-
3% of the activity with oleamide
-
-
?
2-arachidonoylglycerol + H2O
?
show the reaction diagram
-
-
-
-
?
2-arachidonoylglycerol + H2O
?
show the reaction diagram
-
FAAH is responsible for approximately one-half of the 2-arachidonoylglycerol hydrolysis occurring in BV-2 cell homogenate
-
-
?
2-methyloleamide + H2O
2-methyloleic acid + NH3
show the reaction diagram
-
7% of the activity with oleamide
-
-
?
2-oleoylglycerol + H2O
?
show the reaction diagram
-
-
-
-
?
8,11,14-eicosatrienamide + H2O
8,11,14-eicosatrienoic acid + NH3
show the reaction diagram
-
138% of the activity with oleamide
-
-
?
all-trans-anandamide + H2O
ethanolamine + arachidonic acid
show the reaction diagram
-
all-trans-anandamide is an equally good substrate for rabbit platelet FAAH compared to anandamide
-
-
?
alpha-linolenamide + H2O
? + NH3
show the reaction diagram
-
138% of the activity with oleamide
-
-
?
anandamide + H2O
ethanolamine + arachidonic acid
show the reaction diagram
-
-
-
-
?
anandamide + H2O
ethanolamine + arachidonic acid
show the reaction diagram
-
-
-
-
?
anandamide + H2O
ethanolamine + arachidonic acid
show the reaction diagram
-
-
-
-
?
anandamide + H2O
ethanolamine + arachidonic acid
show the reaction diagram
-
-
-
-
?
anandamide + H2O
ethanolamine + arachidonic acid
show the reaction diagram
-
-
-
-
?
anandamide + H2O
ethanolamine + arachidonic acid
show the reaction diagram
O00519, Q6GMR7
-
-
-
?
anandamide + H2O
ethanolamine + arachidonic acid
show the reaction diagram
-
-
-
-
?
anandamide + H2O
ethanolamine + arachidonic acid
show the reaction diagram
O00519, Q6GMR7
FAAH-1 plays a primary role in regulating endocannabinoid signaling
-
-
?
anandamide + H2O
ethanolamine + arachidonic acid
show the reaction diagram
-
anandamide hydrolysis in BV-2 cells is entirely attributable to FAAH
-
-
?
anandamide + H2O
ethanolamine + arachidonic acid
show the reaction diagram
-
enzyme is responsible for the catabolism of neuromodulatory fatty acid amides, including anandamide and oleamide
-
-
?
anandamide + H2O
ethanolamine + arachidonic acid
show the reaction diagram
-
fatty acid amide hydrolase is a modulator of endogenous signaling compounds affecting sleep (oleamide) and analgesia (anandamide)
-
-
?
anandamide + H2O
ethanolamine + arachidonic acid
show the reaction diagram
-
the enzyme cleaves anandamide and regulates in vivo the magnitude and duration of the signaling induced by this lipid messenger
-
-
?
anandamide + H2O
ethanolamine + arachidonic acid
show the reaction diagram
-
the enzyme is responsible for the hydrolysis of a number of neuromodulatory fatty acid amides, including the endogenous cannabinoid anandamide and the sleep-inducing lipid oleamide
-
-
?
anandamide + H2O
ethanolamine + arachidonic acid
show the reaction diagram
-
the serine hydrolase is responsible for the degradation of endogenous oleamide and anandamide, fatty acid amides that function as chemical messengers, 168% of the activity with oleamide
-
-
?
anandamide + H2O
ethanolamine + arachidonic acid
show the reaction diagram
O00519, Q6GMR7
5% of the activity with oleamide
-
-
?
anandamide + H2O
arachidonic acid + ethanolamine
show the reaction diagram
-
-
-
-
?
anandamide + H2O
arachidonic acid + ethanolamine
show the reaction diagram
-
-
-
-
?
anandamide + H2O
arachidonic acid + ethanolamine
show the reaction diagram
-
i.e. N-arachidonoylethanolamine
-
-
?
anandamide + H2O
arachidonic acid + ethanolamine
show the reaction diagram
-
substrate of FAAH and FAAH-2, the latter shows lower activity than FAAH
-
-
?
anandamide + H2O
arachidonic acid + ethanolamine
show the reaction diagram
-
i.e. arachidonoyl ethanolamide
-
-
?
anandamide + H2O
arachidonic acid + ethanolamine
show the reaction diagram
-
i.e. arachidonoyl ethanolamide
-
-
?
anandamide + H2O
arachidonic acid + ethanolamine
show the reaction diagram
-
i.e. arachidonoyl ethanolamide
-
-
?
anandamide + H2O
arachidonic acid + ethanolamine
show the reaction diagram
-
i.e. arachidonoyl ethanolamide
-
-
?
anandamide + H2O
arachidonic acid + ethanolamine
show the reaction diagram
P97612
i.e. arachidonoyl ethanolamide
-
-
?
anandamide + H2O
arachidonic acid + ethanolamine
show the reaction diagram
-
i.e. N-arachidonoyl ethanolamide
-
-
?
anandamide + H2O
arachidonic acid + ethanolamine
show the reaction diagram
-
i.e. arachidonoyl ethanolamide, LC-MS/MS analysis
-
-
?
anandamide + H2O
arachidonic acid + ethanolamine
show the reaction diagram
Rattus norvegicus Sprague-Dawley
-
i.e. arachidonoyl ethanolamide
-
-
?
arachidonamide + H2O
arachidonic acid + NH3
show the reaction diagram
-
-
-
-
?
arachidonamide + H2O
arachidonic acid + NH3
show the reaction diagram
-
311% of the activity with oleamide
-
-
?
arachidonoyl 7-amido-4-methylcoumarine amide + H2O
arachidonoic acid + 7-amino-4-methylcoumarine amide
show the reaction diagram
-
-
-
-
?
arachidonoyl ethanolamide + H2O
arachidonic acid + ethanolamine
show the reaction diagram
-
-
-
-
?
arachidonoyl ethanolamide + H2O
oleic acid + ethanolamine
show the reaction diagram
-
-
-
-
?
arachidonoyl p-nitroanilide + H2O
arachidonate + p-nitroaniline
show the reaction diagram
-
-
-
-
?
beta-arachidonoylglycerol + H2O
?
show the reaction diagram
-
hydrolysis is 2.5fold higher than the rate of anandamide hydrolysis
-
-
?
decanoyl 7-amido-4-methylcoumarin + H2O
?
show the reaction diagram
-
-
-
-
?
decanoyl p-nitroanilide + H2O
decanoate + p-nitroaniline
show the reaction diagram
-
-
-
-
?
dodecanoamide + H2O
dodecanoic acid + NH3
show the reaction diagram
-
74% of the activity with oleamide
-
-
?
erucamide + H2O
? + NH3
show the reaction diagram
-
83% of the activity with oleamide
-
-
?
heptanoyl p-nitroanilide + H2O
heptanoate + p-nitroaniline
show the reaction diagram
-
-
-
-
?
lauroyl p-nitroanilide + H2O
laurate + p-nitroaniline
show the reaction diagram
-
-
-
-
?
linoelaidamide + H2O
(9E,12E)-octadeca-9,12-dienoic acid + NH3
show the reaction diagram
-
54% of the activity with oleamide
-
-
?
myristic amide + H2O
myristic acid + NH3
show the reaction diagram
-
24.3% of the activity with oleamide
-
-
?
myristic amide + H2O
myristic acid + NH3
show the reaction diagram
-
24% of the activity with anandamide
-
-
?
myristic amide + H2O
myristic acid + NH3
show the reaction diagram
-
65% of the activity with anandamide
-
-
?
myristoamide + H2O
myristic acid + NH3
show the reaction diagram
-
83% of the activity with oleamide
-
-
?
myristoleamide + H2O
myristoleic acid + NH3
show the reaction diagram
-
86% of the activity with oleamide
-
-
?
myristoyl p-nitroanilide + H2O
myristate + p-nitroaniline
show the reaction diagram
-
-
-
-
?
N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide + H2O
4-pyren-1-ylbutanoic acid + ?
show the reaction diagram
-
-
-
-
?
N-(2-hydroxyethyl)linoleoylamide + H2O
?
show the reaction diagram
-
-
-
-
?
N-(2-hydroxyethyl)octadecanamide + H2O
?
show the reaction diagram
-
hydrolyzed at 15.0% the rate of anandamide
-
-
?
N-(4-hydroxy-2-methylphenyl) arachidonoyl amide + H2O
4-amino-m-cresol + NH3
show the reaction diagram
-
the rate of metabolism of VDM11 is about 1520% of that for anandamide
-
-
?
N-(o-hydroxyphenyl)arachidonamide + H2O
?
show the reaction diagram
-
-
-
-
?
N-oleoyl ethanolamide + H2O
oleic acid + ethanolamine
show the reaction diagram
-
-
-
-
?
N-oleoylethanolamine + H2O
oleic acid + ethanolamine
show the reaction diagram
O00519, Q6GMR7
23% of the activity with oleamide
-
-
?
N-oleoylethanolamine + H2O
oleic acid + ethanolamine
show the reaction diagram
O00519, Q6GMR7
33% of the activity with anandamide
-
-
?
N-oleoyltaurine + H2O
taurine + oleic acid
show the reaction diagram
O00519, Q6GMR7
4% of the activity with anandamide
-
-
?
N-palmitoyl ethanolamide + H2O
palmic acid + ethanolamine
show the reaction diagram
-
-
-
-
?
N-palmitoylethanolamine + H2O
palmitic acid + ethanolamine
show the reaction diagram
O00519, Q6GMR7
12% of the activity with anandamide
-
-
?
N-palmitoylethanolamine + H2O
palmitic acid + ethanolamine
show the reaction diagram
O00519, Q6GMR7
2.3% of the activity with oleamide
-
-
?
nervonamide + H2O
? + NH3
show the reaction diagram
-
82% of the activity with oleamide
-
-
?
nonanoyl p-nitroanilide + H2O
nonanoate + p-nitroaniline
show the reaction diagram
-
-
-
-
?
octanoyl p-nitroanilide + H2O
octanoate + p-nitroaniline
show the reaction diagram
-
-
-
-
?
oleamide + H2O
oleic acid + NH3
show the reaction diagram
-
-
-
-
?
oleamide + H2O
oleic acid + NH3
show the reaction diagram
-
-
-
-
?
oleamide + H2O
oleic acid + NH3
show the reaction diagram
-
-
-
-
?
oleamide + H2O
oleic acid + NH3
show the reaction diagram
O00519, Q6GMR7
-
-
-
?
oleamide + H2O
oleic acid + NH3
show the reaction diagram
-
enzyme is responsible for the catabolism of neuromodulatory fatty acid amides, including anandamide and oleamide
-
-
?
oleamide + H2O
oleic acid + NH3
show the reaction diagram
-
fatty acid amide hydrolase is a modulator of endogenous signaling compounds affecting sleep (oleamide) and analgesia (anandamide)
-
-
?
oleamide + H2O
oleic acid + NH3
show the reaction diagram
-
role of FAAH in epithelial cells of the choroid plexus may be to control the concentration of oleamide in the cerebrospinal fluid. FAAH may exert an important regulatory role in shaping the duration and magnitude of the sleep-inducing effect of endogenously or exogenously derived oleamide
-
-
?
oleamide + H2O
oleic acid + NH3
show the reaction diagram
-
the enzyme is responsible for the hydrolysis of a number of neuromodulatory fatty acid amides, including the endogenous cannabinoid anandamide and the sleep-inducing lipid oleamide
-
-
?
oleamide + H2O
oleic acid + NH3
show the reaction diagram
-
the serine hydrolase is responsible for the degradation of endogenous oleamide and anandamide, fatty acid amides that function as chemical messengers
-
-
?
oleamide + H2O
oleic acid + NH3
show the reaction diagram
O00519, Q6GMR7
57% of the activity with anandamide
-
-
?
oleamide + H2O
oleic acid + NH3
show the reaction diagram
-
serine residue 241 acts as the catalytic nucleophile of the enzyme. FAAH does not utilize a histidine base for the activation of its serine nucleophile
-
-
?
oleamide + H2O
octadecenoic acid + NH3
show the reaction diagram
P97612
i.e. cis-9-octadecenamide
-
-
?
oleoyl ethanolamide + H2O
arachidonic acid + ethanolamine
show the reaction diagram
-
-
-
-
?
oleoyl ethanolamide + H2O
oleic acid + ethanolamine
show the reaction diagram
-
-
-
-
?
oleoyl methyl amide + H2O
?
show the reaction diagram
-
-
-
-
?
oleoyl methyl ester + H2O
?
show the reaction diagram
-
-
-
-
?
oleoyl methyl ester + H2O
oleic acid + methanol
show the reaction diagram
-
-
-
-
?
oleoyl p-nitroanilide + H2O
?
show the reaction diagram
-
-
-
-
?
oleoyl p-nitroanilide + H2O
oleate + p-nitroaniline
show the reaction diagram
-
-
-
-
?
palmitic acid + H2O
palmitic acid + NH3
show the reaction diagram
-
9.9% of the activity with oleamide
-
-
?
palmitic amide + H2O
palmitic acid + NH3
show the reaction diagram
-
10% of the activity with anandamide
-
-
?
palmitic amide + H2O
palmitic acid + NH3
show the reaction diagram
-
33% of the activity with anandamide
-
-
?
palmitoamide + H2O
palmitoic acid + NH3
show the reaction diagram
-
72% of the activity with oleamide
-
-
?
palmitoleamide + H2O
palmitoleic acid + NH3
show the reaction diagram
-
79% of the activity with oleamide
-
-
?
palmitoyl p-nitroanilide + H2O
palmitate + p-nitroaniline
show the reaction diagram
-
-
-
-
?
palmitoylethanolamide + H2O
palmitic acid + ethanolamine
show the reaction diagram
-
substrate of FAAH and FAAH-2, the latter shows lower activity than FAAH
-
-
?
stearamide + H2O
stearic acid + NH3
show the reaction diagram
-
69% of the activity with oleamide
-
-
?
stearic amide + H2O
stearic acid + NH3
show the reaction diagram
-
5.8% of the activity with anandamide
-
-
?
stearic amide + H2O
stearic acid + NH3
show the reaction diagram
-
5.8% of the activity with oleamide
-
-
?
linoleamide + H2O
? + NH3
show the reaction diagram
-
104% of the activity with oleamide
-
-
?
additional information
?
-
-
catalytic efficiency (kcat/Km) of FAAH for nonanoyl p-nitroanilide is approximately 50fold higher than for hexanoyl p-nitroanilide. NAI491 participates in hydrophobic binding interactions with medium-chain FAAH substrates. Use of p-nitroanilide substrates allows for the precise monitoring of enzymatic hydrolysis rates by following the increase in UV absorbance at 382 nm due to the release of p-nitroaniline. p-Nitroanilides are slower FAAH substrates than the corresponding primary amides, however, the binding affinities of these two classes of substrates are equivalent. Due to the slower rates of p-nitroanilide hydrolysis relative to the corresponding primary amides, it can be assumed that pNA substrates are hydrolyzed by FAAH in an acylation rate-limiting manner, allowing for the direct measurement of substrate binding constants through the determination of Km values
-
-
-
additional information
?
-
-
FAAH is an enzyme of broad substrate specificity and is capable of hydrolyzing a wide array of unsaturated, and to a lesser extent saturated, fatty acid primary amides. However, when substituted adjacent to the amide carbonyl, the substrates can be made sterically or electronically resistant to hydrolysis. Long chain saturated fatty acid amides are hydrolyzed slower than the corresponding Z unsaturated fatty acid amides and the rate of hydrolysis increases incrementally with increases in the degree of unsaturation
-
-
-
additional information
?
-
-
hybrid quantum mechanics/molecular mechanics (QM/MM) calculations reveal a new mechanism of nucleophile activation involving a LysSerSer catalytic triad. The proposed mechanism, shows that Lys142 and cis-Ser217 have a direct role in the activation of Ser241, in agreement with kinetic labelling experiments employing the highly reactive fluorophosphonatetetramethyl rhodamine. The greater reduction of Ser241 labelling rate in the K142A/S217A double mutant, compared to the K142A and S217A single mutants, suggests that Lys142 and Ser217 cooperate to deprotonate Ser241
-
-
-
additional information
?
-
-
N,N-bis(2-hydroxyethyl)arachidonamide is not hydrolyzed
-
-
-
additional information
?
-
O00519, Q6GMR7
no activity with N-oleoyltaurine
-
-
-
additional information
?
-
-
FAAH inactivates anandamide and other bioactive N-acylethanolamines
-
-
-
additional information
?
-
-
the substrate specificity of fatty acid ethanolamides decreased with decreasing length, number of double bonds, and lipophilicity of the fatty acid skeleton
-
-
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
LITERATURE
(Substrate)
COMMENTARY
(Product)
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
2-arachidonoylglycerol + H2O
?
show the reaction diagram
-
FAAH is responsible for approximately one-half of the 2-arachidonoylglycerol hydrolysis occurring in BV-2 cell homogenate
-
-
?
anandamide + H2O
ethanolamine + arachidonic acid
show the reaction diagram
-
-
-
-
?
anandamide + H2O
ethanolamine + arachidonic acid
show the reaction diagram
O00519, Q6GMR7
FAAH-1 plays a primary role in regulating endocannabinoid signaling
-
-
?
anandamide + H2O
ethanolamine + arachidonic acid
show the reaction diagram
-
anandamide hydrolysis in BV-2 cells is entirely attributable to FAAH
-
-
?
anandamide + H2O
ethanolamine + arachidonic acid
show the reaction diagram
-
enzyme is responsible for the catabolism of neuromodulatory fatty acid amides, including anandamide and oleamide
-
-
?
anandamide + H2O
ethanolamine + arachidonic acid
show the reaction diagram
-
fatty acid amide hydrolase is a modulator of endogenous signaling compounds affecting sleep (oleamide) and analgesia (anandamide)
-
-
?
anandamide + H2O
ethanolamine + arachidonic acid
show the reaction diagram
-
the enzyme cleaves anandamide and regulates in vivo the magnitude and duration of the signaling induced by this lipid messenger
-
-
?
anandamide + H2O
ethanolamine + arachidonic acid
show the reaction diagram
-
the enzyme is responsible for the hydrolysis of a number of neuromodulatory fatty acid amides, including the endogenous cannabinoid anandamide and the sleep-inducing lipid oleamide
-
-
?
anandamide + H2O
ethanolamine + arachidonic acid
show the reaction diagram
-
the serine hydrolase is responsible for the degradation of endogenous oleamide and anandamide, fatty acid amides that function as chemical messengers
-
-
?
anandamide + H2O
arachidonic acid + ethanolamine
show the reaction diagram
-
-
-
-
?
anandamide + H2O
arachidonic acid + ethanolamine
show the reaction diagram
-
-
-
-
?
anandamide + H2O
arachidonic acid + ethanolamine
show the reaction diagram
-
i.e. N-arachidonoylethanolamine
-
-
?
anandamide + H2O
arachidonic acid + ethanolamine
show the reaction diagram
-
substrate of FAAH and FAAH-2, the latter shows lower activity than FAAH
-
-
?
anandamide + H2O
arachidonic acid + ethanolamine
show the reaction diagram
-
i.e. arachidonoyl ethanolamide
-
-
?
anandamide + H2O
arachidonic acid + ethanolamine
show the reaction diagram
-
i.e. arachidonoyl ethanolamide
-
-
?
anandamide + H2O
arachidonic acid + ethanolamine
show the reaction diagram
-
i.e. arachidonoyl ethanolamide
-
-
?
anandamide + H2O
arachidonic acid + ethanolamine
show the reaction diagram
-
i.e. arachidonoyl ethanolamide
-
-
?
anandamide + H2O
arachidonic acid + ethanolamine
show the reaction diagram
P97612
i.e. arachidonoyl ethanolamide
-
-
?
anandamide + H2O
arachidonic acid + ethanolamine
show the reaction diagram
-
i.e. N-arachidonoyl ethanolamide
-
-
?
N-oleoyl ethanolamide + H2O
oleic acid + ethanolamine
show the reaction diagram
-
-
-
-
?
N-palmitoyl ethanolamide + H2O
palmic acid + ethanolamine
show the reaction diagram
-
-
-
-
?
oleamide + H2O
oleic acid + NH3
show the reaction diagram
-
-
-
-
?
oleamide + H2O
oleic acid + NH3
show the reaction diagram
-
enzyme is responsible for the catabolism of neuromodulatory fatty acid amides, including anandamide and oleamide
-
-
?
oleamide + H2O
oleic acid + NH3
show the reaction diagram
-
fatty acid amide hydrolase is a modulator of endogenous signaling compounds affecting sleep (oleamide) and analgesia (anandamide)
-
-
?
oleamide + H2O
oleic acid + NH3
show the reaction diagram
-
role of FAAH in epithelial cells of the choroid plexus may be to control the concentration of oleamide in the cerebrospinal fluid. FAAH may exert an important regulatory role in shaping the duration and magnitude of the sleep-inducing effect of endogenously or exogenously derived oleamide
-
-
?
oleamide + H2O
oleic acid + NH3
show the reaction diagram
-
the enzyme is responsible for the hydrolysis of a number of neuromodulatory fatty acid amides, including the endogenous cannabinoid anandamide and the sleep-inducing lipid oleamide
-
-
?
oleamide + H2O
oleic acid + NH3
show the reaction diagram
-
the serine hydrolase is responsible for the degradation of endogenous oleamide and anandamide, fatty acid amides that function as chemical messengers
-
-
?
oleamide + H2O
octadecenoic acid + NH3
show the reaction diagram
P97612
i.e. cis-9-octadecenamide
-
-
?
palmitoylethanolamide + H2O
palmitic acid + ethanolamine
show the reaction diagram
-
substrate of FAAH and FAAH-2, the latter shows lower activity than FAAH
-
-
?
anandamide + H2O
arachidonic acid + ethanolamine
show the reaction diagram
Rattus norvegicus Sprague-Dawley
-
i.e. arachidonoyl ethanolamide
-
-
?
additional information
?
-
-
FAAH inactivates anandamide and other bioactive N-acylethanolamines
-
-
-
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
(1-benzothiophen-6-ylamino)([(E)-[1-(biphenyl-3-yl)ethylidene]amino]oxy)methanone
-
-
(1-benzylpiperidin-4-yl)[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl]methanone
-
-
(10Z)-1,1,1-trifluorononadec-10-en-2-one
-
-
(10Z)-1-bromononadec-10-en-2-one
-
-
(10Z)-2-oxononadec-10-enamide
-
-
(2R)-oxiran-2-ylmethyl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate
-
-
(2S)-oxiran-2-ylmethyl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate
-
-
(4-benzylpiperazin-1-yl)[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl]methanone
-
-
(5E)-5-(4-methoxybenzylidene)-3-[1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indol-5-yl]-1,3-thiazolidine-2,4-dione
-
-
(5Z,8Z,11Z,14Z)-1-pyridazin-3-ylicosa-5,8,11,14-tetraen-1-one
-
-
(5Z,8Z,11Z,14Z)-1-[1,3]oxazolo[4,5-b]pyridin-2-ylicosa-5,8,11,14-tetraen-1-one
-
-
(5Z,8Z,11Z,14Z)-1-[1,3]oxazolo[4,5-c]pyridin-2-ylicosa-5,8,11,14-tetraen-1-one
-
-
(5Z,8Z,11Z,14Z)-1-[1,3]oxazolo[5,4-c]pyridin-2-ylicosa-5,8,11,14-tetraen-1-one
-
-
(5Z,8Z,11Z,14Z)-N-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)icosa-5,8,11,14-tetraenamide
-
-
(5Z,8Z,11Z,14Z)-N-(2-hydroxyethyl)icosa-5,8,11,14-tetraenamide
-
i.e. (5Z,8Z,11Z,14Z)-N-(2-hydroxyethyl)icosa-5,8,11,14-tetraenamide or N-arachidonoylethanolamine, competitive
(5Z,8Z,11Z,14Z)-N-[(2R)-tetrahydrofuran-2-ylmethyl]icosa-5,8,11,14-tetraenamide
-
-
(5Z,8Z,11Z,14Z)-N-[(2S)-tetrahydrofuran-2-ylmethyl]icosa-5,8,11,14-tetraenamide
-
-
(6aR,10aR)-3-(1,1-dimethylheptyl)-9-(hydroxymethyl)-6,6-dimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-1-ol
-
-
(9E)-1-pyridazin-3-yloctadec-9-en-1-one
-
-
(9E)-1-[1,3]oxazolo[4,5-b]pyridin-2-yloctadec-9-en-1-one
-
-
(9Z)-1-(1,3-benzothiazol-2-yl)octadec-9-en-1-one
-
-
(9Z)-1-(1,3-benzoxazol-2-yl)octadec-9-en-1-one
-
-
(9Z)-1-(1,3-oxazol-2-yl)octadec-9-en-1-one
-
-
(9Z)-1-(1,3-thiazol-2-yl)octadec-9-en-1-one
-
-
(9Z)-1-(1-methyl-1H-benzimidazol-2-yl)octadec-9-en-1-one
-
-
(9Z)-1-(1-methyl-1H-imidazol-2-yl)octadec-9-en-1-one
-
-
(9Z)-1-(1-methyl-1H-tetrazol-5-yl)octadec-9-en-1-one
-
-
(9Z)-1-(1H-benzimidazol-2-yl)octadec-9-en-1-one
-
-
(9Z)-1-(1H-tetrazol-5-yl)octadec-9-en-1-one
-
-
(9Z)-1-(2-methyl-2H-tetrazol-5-yl)octadec-9-en-1-one
-
-
(9Z)-1-(4,5-dihydro-1,3-oxazol-2-yl)octadec-9-en-1-one
-
-
(9Z)-1-(4-methyl-1,3-benzoxazol-2-yl)octadec-9-en-1-one
-
-
(9Z)-1-(5-methyl-1,3-benzoxazol-2-yl)octadec-9-en-1-one
-
-
(9Z)-1-(6-methyl-1,3-benzoxazol-2-yl)octadec-9-en-1-one
-
-
(9Z)-1-(7-methyl-1,3-benzoxazol-2-yl)octadec-9-en-1-one
-
-
(9Z)-1-phenyloctadec-9-en-1-one
-
-
(9Z)-1-pyrazin-2-yloctadec-9-en-1-one
-
-
(9Z)-1-pyridazin-3-yloctadec-9-en-1-one
-
-
(9Z)-1-pyridin-2-yloctadec-9-en-1-one
-
-
(9Z)-1-pyrimidin-2-yloctadec-9-en-1-one
-
-
(9Z)-1-pyrimidin-4-yloctadec-9-en-1-one
-
-
(9Z)-1-[1,3]oxazolo[4,5-b]pyridin-2-yloctadec-9-en-1-one
-
-
(9Z)-1-[1,3]oxazolo[4,5-c]pyridin-2-yloctadec-9-en-1-one
-
-
(9Z)-1-[1,3]oxazolo[5,4-b]pyridin-2-yloctadec-9-en-1-one
-
-
(9Z)-1-[1,3]oxazolo[5,4-c]pyridin-2-yloctadec-9-en-1-one
-
-
(9Z)-octadec-9-enal
-
-
(dodecylamino)[[(E)-[1-[3-(thiophen-2-yl)phenyl]ethylidene]amino]oxy]methanone
-
-
(phenylamino)[[(4-phenylcyclohexylidene)amino]oxy]methanone
-
-
(phenylamino)[[(E)-[1-[3-(thiophen-2-yl)phenyl]ethylidene]amino]oxy]methanone
-
-
(phenylamino)[[(E)-[1-[4-(thiophen-2-yl)phenyl]ethylidene]amino]oxy]methanone
-
-
(R,S)-ibuprofen
-
-
([(E)-[1-(2,2'-bithiophen-5-yl)ethylidene]amino]oxy)(naphthalen-1-ylamino)methanone
-
-
([(E)-[1-(4-cyclohexylphenyl)ethylidene]amino]oxy)(naphthalen-1-ylamino)methanone
-
-
([(E)-[1-(biphenyl-3-yl)ethylidene]amino]oxy)(diphenylamino)methanone
-
-
([(E)-[1-(biphenyl-3-yl)ethylidene]amino]oxy)(naphthalen-1-ylamino)methanone
-
-
([(E)-[1-(biphenyl-3-yl)ethylidene]amino]oxy)(phenylamino)methanone
-
-
([(E)-[1-(biphenyl-3-yl)ethylidene]amino]oxy)(piperidin-1-yl)methanone
-
-
([(E)-[1-(biphenyl-3-yl)ethylidene]amino]oxy)[(4-fluorophenyl)amino]methanone
-
-
([(E)-[1-(biphenyl-3-yl)ethylidene]amino]oxy)[(4-methoxyphenyl)amino]methanone
-
-
([(E)-[1-(biphenyl-3-yl)ethylidene]amino]oxy)[(5-phenylpentyl)amino]methanone
-
-
([(E)-[1-(biphenyl-4-yl)ethylidene]amino]oxy)(dimethylamino)methanone
-
-
([(E)-[1-(biphenyl-4-yl)ethylidene]amino]oxy)(naphthalen-1-ylamino)methanone
-
-
([(E)-[1-(biphenyl-4-yl)ethylidene]amino]oxy)(phenylamino)methanone
-
-
1,1'-(5,5'-bi-1,3-oxazole-2,2'-diyl)bis(7-phenylheptan-1-one)
-
-
1,1-biphenyl-3-yl-carbamic acid cyclohexyl ester
-
i.e. URB602
1,3-benzodioxol-5-ylmethyl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate
-
-
1-(1,3-benzoxazol-2-yl)octadecan-1-one
-
-
1-(1,3-oxazol-2-yl)-7-phenylheptan-1-one
-
-
1-(2-oxo-3-[4-[4-(trifluoromethyl)phenoxy]phenoxy]propyl)-1H-indole-5-carboxylic acid
-
21% inhibition at 0.01 mM
1-(2-oxo-3-[[4'-(propan-2-yl)biphenyl-4-yl]oxy]propyl)-1H-indole-5-carboxylic acid
-
-
1-(4-octylphenoxy)-3-[5-(1H-tetrazol-5-yl)-1H-indol-1-yl]propan-2-one
-
-
1-(5-acetyl-1,3-oxazol-2-yl)-7-phenylheptan-1-one
-
-
1-(5-bromo-1,3-oxazol-2-yl)-7-phenylheptan-1-one
-
-
1-(5-chloro-1,3-oxazol-2-yl)-7-phenylheptan-1-one
-
-
1-(5-fluoro-1,3-oxazol-2-yl)-7-phenylheptan-1-one
-
-
1-(5-furan-2-yl-1,3-oxazol-2-yl)-7-phenylheptan-1-one
-
-
1-(5-iodo-1,3-oxazol-2-yl)-7-phenylheptan-1-one
-
-
1-(5-methyl-1,3-oxazol-2-yl)-7-phenylheptan-1-one
-
-
1-([1,3]oxazolo[4,5-b]pyridin-2-yl)-6-phenylhexan-1-one
-
-
1-oxazolo[4,5-b]pyridin-2-yl-9-octadecyn-1-one
-
-
1-pyridazin-3-yloctadecan-1-one
-
-
1-[(3S)-1-[4-(1-benzofuran-2-yl)pyrimidin-2-yl]piperidin-3-yl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one
-
the compound belongs to the ketobenzimidazoles, though containing a carbonyl moiety, that do not covalently modify Ser241. These inhibitors achieve potent inhibition of FAAH activity primarily from shape complementarity to the active site and through numerous hydrophobic interactions exhibiting excellent selectivity and good pharmacokinetic properties, nonmechanism-based inhibition
1-[(3S)-1-[4-(1-benzofuran-2-yl)pyrimidin-2-yl]piperidin-3-yl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one
-
the compound belongs to the ketobenzimidazoles, though containing a carbonyl moiety, that do not covalently modify Ser241. These inhibitors achieve potent inhibition of FAAH activity primarily from shape complementarity to the active site and through numerous hydrophobic interactions exhibiting excellent selectivity and good pharmacokinetic properties, nonmechanism-based inhibition. Pharmacokinetic parameters and selectivity 2, overview
1-[1,3]oxazolo[4,5-b]pyridin-2-yl-4-phenylbutan-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-yl-5-phenylpentan-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-yl-6-phenylhexan-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-yl-7-phenylheptan-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-yl-8-phenyloctan-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-yl-9-phenylnonan-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-yldec-9-en-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-yldec-9-yn-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-yldecan-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-yldodecan-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-ylethanone
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-ylheptan-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-ylhexadecan-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-ylhexan-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-yloctadec-9-yn-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-yloctadecan-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-yloctan-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-ylpentan-1-one
-
-
1-[1,3]oxazolo[4,5-b]pyridin-2-yltetradecan-1-one
-
-
1-[1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indol-5-yl]-1H-benzimidazole-7-carboxylic acid
-
-
1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indole-5-carboxylic acid
-
-
1-[2-oxo-3-[4-(2-phenoxyethoxy)phenoxy]propyl]-1H-indole-5-carboxylic acid
-
-
1-[2-oxo-3-[4-(2-phenylpropan-2-yl)phenoxy]propyl]-1H-indole-5-carboxylic acid
-
-
1-[3-(4-benzylphenoxy)-2-oxopropyl]-1H-indole-5-carboxylic acid
-
-
1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indazole-5-carboxylic acid
-
-
1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-carboxamide
-
-
1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-carboxylic acid
-
-
1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-sulfonamide
-
-
1-[3-(4-octylphenoxy)-2-oxopropyl]indole-5-carboxylic acid
-
-
1-[3-(4-octylphenoxy)-2-oxopropyl]indole-5-carboxylic acid
-
structure-activity relationship, overview
1-[3-(biphenyl-2-yloxy)-2-oxopropyl]-1H-indole-5-carboxylic acid
-
-
1-[3-(biphenyl-3-yloxy)-2-oxopropyl]-1H-indole-5-carboxylic acid
-
-
1-[3-(biphenyl-4-yloxy)-2-oxopropyl]-1H-indole-5-carboxylic acid
-
-
1-[3-[(3'-chlorobiphenyl-4-yl)oxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
-
1-[3-[(3'-fluorobiphenyl-4-yl)oxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
-
1-[3-[(3-chlorobiphenyl-4-yl)oxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
-
1-[3-[(3-fluorobiphenyl-4-yl)oxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
-
1-[3-[(3-methoxybiphenyl-4-yl)oxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
-
1-[3-[(3-methylbiphenyl-4-yl)oxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
39% inhibition at 0.01 mM
1-[3-[(4'-chlorobiphenyl-4-yl)oxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
-
1-[3-[(4'-chlorobiphenyl-4-yl)oxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
-
1-[3-[(4'-fluorobiphenyl-4-yl)oxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
-
1-[3-[(4'-methoxybiphenyl-4-yl)oxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
-
1-[3-[(4'-methylbiphenyl-4-yl)oxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
-
1-[3-[4-(4-fluorophenyl)phenoxy]-2-oxopropyl]indazole-5-carboxylic acid
-
-
1-[3-[4-(decyloxy)phenoxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
-
1-[3-[4-(heptyloxy)phenoxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
-
1-[3-[4-(hexyloxy)phenoxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
-
1-[3-[4-(nonyloxy)phenoxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
-
1-[3-[4-(octyloxy)phenoxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
-
1-[5-(2,4-dimethoxypyrimidin-5-yl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
1-[5-(2,6-dimethoxypyrimidin-4-yl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
1-[5-(2-aminophenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
1-[5-(2-fluorophenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
1-[5-(2-hydroxyphenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
1-[5-(2-methoxyphenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
1-[5-(2-nitrophenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
1-[5-(3-aminophenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
1-[5-(3-benzyl-1,2,4-oxadiazol-5-yl)-1H-indol-1-yl]-3-(4-octylphenoxy)propan-2-one
-
-
1-[5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1H-indol-1-yl]-3-(4-octylphenoxy)propan-2-one
-
-
1-[5-(3-fluorophenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
1-[5-(3-hydroxyphenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
1-[5-(3-methoxyphenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
1-[5-(3-methylpyridin-2-yl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
1-[5-(3-nitrophenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
1-[5-(4-aminophenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
1-[5-(4-aminopyridin-2-yl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
1-[5-(4-fluorophenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
1-[5-(4-fluoropyridin-2-yl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
1-[5-(4-hydroxyphenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
1-[5-(4-methoxyphenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
1-[5-(4-methoxypyridin-2-yl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
1-[5-(4-methylpyridin-2-yl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
1-[5-(4-nitrophenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
1-[5-(4-nitropyridin-2-yl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
1-[5-(5-methylpyridin-2-yl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
1-[5-(6-methylpyridin-2-yl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
1-[5-(methylsulfanyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
1-[5-(morpholin-4-ylcarbonyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
1-[5-(morpholin-4-ylcarbonyl)-1H-indol-1-yl]-3-(4-octylphenoxy)propan-2-one
-
-
1-[5-[(4-methylpiperazin-1-yl)carbonyl]-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
2,2-dimethyl-1,3-dioxolan-4-ylmethyl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate
-
-
2-(5,5-dimethyl-1,3-dioxan-2-yl)ethyl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate
-
-
2-(7-phenylheptanoyl)-1,3-oxazole-5-carbaldehyde
-
-
2-(7-phenylheptanoyl)-1,3-oxazole-5-carbonitrile
-
-
2-(7-phenylheptanoyl)-1,3-oxazole-5-carboxamide
-
-
2-(7-phenylheptanoyl)-1,3-oxazole-5-carboxylic acid
-
-
2-iodobenzylarachidonoylamide
-
-
2-iodobenzyllinoleoylamide
-
-
2-iodophenethylarachidonoylamide
-
-
2-iodophenethyllinoleoylamide
-
-
2-methoxyphenethylarachidonoylamide
-
-
2-methoxyphenethyllinoleoylamide
-
-
2-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzamide
-
-
2-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzenesulfonamide
-
-
2-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzoic acid
-
-
2-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzonitrile
-
-
2-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyridine-3-carboxylic acid
-
-
2-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyridine-4-carbonitrile
-
-
2-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyridine-4-carboxylic acid
-
-
3'-carbamoyl-biphenyl-3-yl-cyclohexylcarbamate
-
-
3'-carbamoylbiphenyl-3-yl cyclohexylcarbamate
-
-
3'-carbamoylbiphenyl-3-yl cyclohexylcarbamate
-
-
3'-carbamoylbiphenyl-3-yl undec-10-yn-1-ylcarbamate
-
-
3'-[(1E)-N-[(phenylcarbamoyl)oxy]ethanimidoyl]biphenyl-3-carboxamide
-
-
3-iodobenzylarachidonoylamide
-
-
3-iodobenzyllinoleoylamide
-
-
3-iodophenethylarachidonoylamide
-
-
3-iodophenethyllinoleoylamide
-
-
3-methoxyphenethylarachidonoylamide
-
-
3-methoxyphenethyllinoleoylamide
-
-
3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N,N-diethylazetidine-1-carboxamide
-
-
3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-ethyl-N-(2-hydroxyethyl)azetidine-1-carboxamide
-
-
3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-methyl-N-(2-phenylethyl)azetidine-1-carboxamide
-
-
3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-methyl-N-phenylazetidine-1-carboxamide
-
-
3-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzamide
-
-
3-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzenesulfonamide
-
-
3-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzoic acid
-
-
3-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzonitrile
-
-
4-(3-phenyl-[1,2,4]thiadiazol-5-yl)piperazine-1-carboxylic acid phenylamide
-
-
4-(3-phenyl-[1,2,4]thiadiazol-5-yl)piperazine-1-carboxylic acid phenylamide
-
JNJ-1661010
4-(acetylamino)phenyl (4-[[2-(trifluoromethyl)pyridin-4-yl]amino]phenyl)acetate
-
-
4-(acetylamino)phenyl 2-(4-[[2-(trifluoromethyl)pyridin-4-yl]amino]phenyl)propanoate
-
competitive, also able to inhibit the FAAH activity in rat basophilic leukemia cells as assessed by measuring either the hydrolysis of anandamide, the FAAH-dependent cellular accumulation of anandamide, or the FAAH-dependent recycling of tritium to the cellmembranes
4-(acetylamino)phenyl 2-[[2-(trifluoromethyl)pyridin-4-yl]amino]pyridine-3-carboxylate
-
-
4-(acetylamino)phenyl 2-[[3-(trifluoromethyl)phenyl]amino]benzoate
-
-
4-(acetylamino)phenyl 2-[[3-(trifluoromethyl)phenyl]amino]pyridine-3-carboxylate
-
-
4-(acetylamino)phenyl 2-{[2-(trifluoromethyl)pyridin-4-yl]amino}benzoate
-
-
4-(acetylamino)phenyl 3-(4-[[2-(trifluoromethyl)pyridin-4-yl]amino]phenyl)propanoate
-
-
4-(acetylamino)phenyl 3-methyl-4-[[2-(trifluoromethyl)pyridin-4-yl]amino]benzoate
-
-
4-(acetylamino)phenyl 3-[[2-(trifluoromethyl)pyridin-4-yl]amino]benzoate
-
-
4-(acetylamino)phenyl 4-([[2-(trifluoromethyl)pyridin-4-yl]amino]methyl)benzoate
-
-
4-(acetylamino)phenyl 4-chloro-2-[[2-(trifluoromethyl)pyridin-4-yl]amino]benzoate
-
-
4-(acetylamino)phenyl 4-[[2-(trifluoromethyl)pyridin-4-yl]amino]benzoate
-
-
4-(acetylamino)phenyl 5-chloro-2-[[2-(trifluoromethyl)pyridin-4-yl]amino]benzoate
-
-
4-(acetylamino)phenyl 5-methyl-2-[[2-(trifluoromethyl)pyridin-4-yl]amino]benzoate
-
-
4-(acetylamino)phenyl N-(3-methyl-4-[[2-(trifluoromethyl)pyridin-4-yl]amino]benzoyl)glycinate
-
-
4-(acetylamino)phenyl N-(4-[[2-(trifluoromethyl)pyridin-4-yl]amino]benzoyl)glycinate
-
-
4-(acetylamino)phenyl N-[(4-[[2-(trifluoromethyl)pyridin-4-yl]amino]phenyl)acetyl]glycinate
-
-
4-(acetylamino)phenyl N-[2-(4-[[2-(trifluoromethyl)pyridin-4-yl]amino]phenyl)propanoyl]glycinate
-
-
4-(benzyloxy)phenyl butylcarbamate
-
-
4-iodobenzylarachidonoylamide
-
-
4-iodobenzyllinoleoylamide
-
-
4-iodophenethylarachidonoylamide
-
-
4-iodophenethyllinoleoylamide
-
-
4-methoxyphenethylarachidonoylamide
-
-
4-methoxyphenethyllinoleoylamide
-
-
4-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzamide
-
-
4-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzenesulfonamide
-
-
4-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzoic acid
-
-
4-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzonitrile
-
-
4-[3-[4-(decyloxy)phenoxy]-2-oxopropoxy]benzoic acid
-
-
5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-morpholin-4-yl-1H-pyrazole-3-carboxamide
-
-
5-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]furan-2-carboxylic acid
-
-
5-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyrimidine-2,4(1H,3H)-dione
-
-
5-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]thiophene-2-carboxylic acid
-
-
5-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]thiophene-2-sulfonamide
-
-
6-bromo-N-(2-fluorophenyl)-1'H,4H-spiro[1,3-benzodioxine-2,4'-piperidine]-1'-carboxamide
-
an irreversible covalent inhibitor, binding structure, overview
6-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyridine-2-carboxamide
-
-
6-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyridine-2-carboxylic acid
-
-
6-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyridine-3-carboxamide
-
-
6-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyridine-3-carboxylic acid
-
-
6-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyrimidine-2,4(1H,3H)-dione
-
-
7-phenyl-1-(5-phenyl-1,3-oxazol-2-yl)heptan-1-one
-
-
7-phenyl-1-(5-pyridin-2-yl-1,3-oxazol-2-yl)heptan-1-one
-
-
7-phenyl-1-(5-pyridin-2-yl-1,3-oxazol-2-yl)heptan-1-one
-
-
7-phenyl-1-(5-pyrimidin-2-yl-1,3-oxazol-2-yl)heptan-1-one
-
-
7-phenyl-1-(5-pyrimidin-4-yl-1,3-oxazol-2-yl)heptan-1-one
-
-
7-phenyl-1-(5-pyrimidin-5-yl-1,3-oxazol-2-yl)heptan-1-one
-
-
7-phenyl-1-(5-thiophen-2-yl-1,3-oxazol-2-yl)heptan-1-one
-
-
7-phenyl-1-[5-(1H-tetrazol-5-yl)-1,3-oxazol-2-yl]heptan-1-one
-
-
7-phenyl-1-[5-(piperidin-1-ylcarbonyl)-1,3-oxazol-2-yl]heptan-1-one
-
-
7-phenyl-1-[5-(pyridin-2-yl)-1,3-oxazol-2-yl]heptan-1-one
-
; OL-135, an alpha-keto-heterocycle that is a covalent reversible inhibitor of FAAH
7-phenyl-1-[5-(pyridin-2-yl)-1,3-oxazol-2-yl]heptan-1-one
-
OL-135, an alpha-keto-heterocycle that is a covalent reversible inhibitor of FAAH
7-phenyl-1-[5-(thiomorpholin-4-ylcarbonyl)-1,3-oxazol-2-yl]heptan-1-one
-
-
7-phenyl-1-[5-(trifluoroacetyl)-1,3-oxazol-2-yl]heptan-1-one
-
-
7-phenyl-1-[5-(trifluoromethyl)-1,3-oxazol-2-yl]heptan-1-one
-
-
7-phenyl-1-[5-[2-(trifluoroacetyl)phenyl]-1,3-oxazol-2-yl]heptan-1-one
-
-
7-phenyl-1-[5-[3-(trifluoroacetyl)phenyl]-1,3-oxazol-2-yl]heptan-1-one
-
-
7-phenyl-1-[5-[4-(trifluoroacetyl)phenyl]-1,3-oxazol-2-yl]heptan-1-one
-
-
7-phenyl-1-[5-[4-(trifluoromethyl)pyridin-2-yl]-1,3-oxazol-2-yl]heptan-1-one
-
-
azepan-1-yl[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl]methanone
-
-
azetidin-1-yl[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl]methanone
-
-
benzol
-
-
chlorpyrifos oxon
-
-
cis-anandamide
-
inhibits hydrolysis of anandamide
cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester
-
i.e. URB597, attenuates the development of lipopolysaccharide-induced paw edema and reverses lipopolysaccharide-induced hyperalgesia through the respective CB2 and CB1 mechanisms of action. The inhibition is not affected by capsazepine, a transient receptor potential vanilloid type 1 antagonist
decyl benzodioxaphosphorin oxide
-
-
diazoxon
-
-
dichlorvos
-
-
diisopropyl fluorophosphate
-
-
dodecyl benzodioxaphosphorin oxide
-
-
dodecyl sulfonyl fluoride
-
-
dodecyl-benzodioxaphosphorin oxide
-
-
ethoxy oleoyl fluorophosphonate
-
irreversible inhibitor, exclusively modifies FAAH at S241
ethyl (10Z)-2-oxononadec-10-enoate
-
-
ethyl octylphosphonofluoridate
-
-
heptyl benzodioxaphosphorin oxide
-
-
Ibuprofen
-
-
isopropyl dodecylfluorophosphate
-
-
JP104
-
-
methyl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraen-1-ylphosphonofluoridate
-
-
methyl 2-(7-phenylheptanoyl)-1,3-oxazole-5-carboxylate
-
-
methyl 2-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzoate
-
-
methyl 2-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyridine-3-carboxylate
-
-
methyl 2-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyridine-4-carboxylate
-
-
methyl 3-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzoate
-
-
methyl 4-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzoate
-
-
methyl 5-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]furan-2-carboxylate
-
-
methyl 5-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]thiophene-2-carboxylate
-
-
methyl 6-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyridine-2-carboxylate
-
-
methyl 6-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyridine-3-carboxylate
-
-
methyl arachidonyl fluorophosphonate
-
-
methyl arachidonyl fluorophosphonate
-
MAFP, a potent irreversible FAAH inhibitor
methyl arachidonyl phosphonofluoridate
-
-
methyl arachidonylfluoroposphate
-
-
N,N-dibenzyl-3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidine-1-carboxamide
-
-
N,N-dimethyl-1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-carboxamide
-
-
N,N-dimethyl-1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-sulfonamide
-
-
N,N-dimethyl-2-(7-phenylheptanoyl)-1,3-oxazole-5-carboxamide
-
-
N-(2-hydroxyethyl)linoleoylamide
-
competitive versus anadamide
N-(3-methylpyridin-2-yl)-2-(4'-isobutylphenyl)propionamide
-
i.e. Ibu-am5
N-(4-hydroxy-2-methylphenyl) arachidonoyl amide
-
i.e. VDM11, inhibits the metabolism of anandamide by rat brain FAAH. Inhibition may at least in part be a consequence of the compound acting as an alternative substrate
N-(4-hydroxyphenyl)-5Z,8Z,11Z,14Z-eicosatetraenamide
-
i.e. AM404, a bioactive N-acylphenolamine, derived from paracetamol, competitve inhibition
N-(4-hydroxyphenyl)arachidonylamide
-
i.e. AM404, inhibits the metabolism of anandamide by rat brain FAAH
N-(phenylcarbamoyl)-3'-[(1E)-N-[(phenylcarbamoyl)oxy]ethanimidoyl]biphenyl-3-carboxamide
-
-
N-benzyl-3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-(2-hydroxyethyl)azetidine-1-carboxamide
-
-
N-benzyl-3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-methylazetidine-1-carboxamide
-
-
N-benzyl-3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-[2-(dimethylamino)ethyl]azetidine-1-carboxamide
-
-
N-benzyl-3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidine-1-carboxamide
-
-
N-benzyl-3-[(R)-(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-methylazetidine-1-carboxamide
-
-
N-benzyl-3-[(S)-(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-methylazetidine-1-carboxamide
-
-
N-methyl-1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-carboxamide
-
-
N-methyl-1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-sulfonamide
-
-
N-methyl-2-(7-phenylheptanoyl)-1,3-oxazole-5-carboxamide
-
-
N-n-heptyl benzodioxaphosphorin oxide
-
-
N-tert-butyl-3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidine-1-carboxamide
-
-
N-[4-(4-methoxy-1,3-benzothiazol-2-yl)phenyl]-1-(thiophen-2-ylsulfonyl)piperidine-4-carboxamide
-
a reversible, albeit slowly dissociating inhibitor of FAAH, reversibly and noncovalently inhibiting, molecular docking and computational modeling of interactions of the benzothiazole analogue 1 with humanized rat FAAH by induced fit docking, overview. Failure to observe the formation of covalent enzyme-inhibitor adduct or putative cleavage product using electrospray mass spectrometric techniques
O-n-octyl benzodioxaphosphorin oxide
-
-
O-octyl-benzodioxaphosphorin oxide
-
-
octyl sulfonyl fluoride
-
-
octyl-benzodioxaphosphorin oxide
-
-
OL-135
-
-
OL-135
-
7-phenyl-1-[5-(pyridin-2-yl)-1,3-oxazol-2-yl]heptan-1-one
oleoyl ethylamide
-
FAAH inhibitor
-
oleoyl oxazolopyridine
-
i.e. oloxa, a potent noncompetitive inhibitor, almost complete inhibition at 50 nM
-
oleoyl oxazolopyridine
-
, i.e. oloxa, a potent noncompetitive inhibitor, almost complete inhibition at 50 nM
-
oleyl-benzodioxaphosphorin oxide
-
-
oxiran-2-ylmethyl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate
-
-
oxiran-2-ylmethyl (9Z)-hexadec-9-enoate
-
-
oxiran-2-ylmethyl (9Z)-octadec-9-enoate
-
-
oxiran-2-ylmethyl (9Z,12Z)-octadeca-9,12-dienoate
-
-
oxiran-2-ylmethyl (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
-
-
oxiran-2-ylmethyl 1,1'-biphenyl-2-carboxylate
-
-
oxiran-2-ylmethyl 1,1'-biphenyl-3-carboxylate
-
-
oxiran-2-ylmethyl 1,1'-biphenyl-4-carboxylate
-
-
oxiran-2-ylmethyl benzoate
-
-
palmitoyl ethanolamide
-
a non-CB1 non-CB2 cannabinoid-like compound
-
Paraoxon
-
-
PF-3845
-
FAAH inhibitor, in vivo inhibition
-
PF-3845
P97612
crystal structure analysis of enzyme-inhibitor complex. The inhibitor interacts with the catalytic triad and oxyanion hole residues
-
phenyl-benzodioxaphosphorin oxide
-
-
piperidin-1-yl[[(E)-[1-[3-(thiophen-2-yl)phenyl]ethylidene]amino]oxy]methanone
-
-
profenofos
-
-
S-heptyl benzodioxaphosphorin oxide
-
-
S-nonyl benzodioxaphosphorin oxide
-
-
S-pentyl benzodioxaphosphorin oxide
-
-
stearyl benzodioxaphosphorin oxide
-
-
tetrahydro-2H-pyran-2-ylmethyl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate
-
-
tetrahydro-2H-pyran-2-ylmethyl (9Z)-hexadec-9-enoate
-
-
tetrahydro-2H-pyran-2-ylmethyl (9Z)-octadec-9-enoate
-
-
tetrahydro-2H-pyran-2-ylmethyl (9Z,12Z)-octadeca-9,12-dienoate
-
-
tetrahydro-2H-pyran-2-ylmethyl (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
-
-
tetrahydro-2H-pyran-2-ylmethyl 1,1'-biphenyl-2-carboxylate
-
-
tetrahydro-2H-pyran-2-ylmethyl 1,1'-biphenyl-3-carboxylate
-
-
tetrahydro-2H-pyran-2-ylmethyl 1,1'-biphenyl-4-carboxylate
-
-
tetrahydro-2H-pyran-2-ylmethyl benzoate
-
-
tetrahydro-2H-pyran-4-yl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate
-
-
trans-anandamide
-
inhibits hydrolysis of anandamide
URB524
P97612
-
-
URB532
-
-
URB597
-
a carbamate inhibiting FAAH covalently and irreversibly, time-dependent inhibition, overview
URB597
P97612
a carbamate inhibitor that displays excellent selectivity for FAAH in the nervous system, although the inhibitor does inactivate additional peripheral hydrolases, enzyme-inhibitor binding structure, overview. The inhibitor interacts with the catalytic triad and oxyanion hole residues
VER-156084
-
a tetrasubstituted azetidine urea FAAH inhibitor
-
[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate
-
-
[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate
-
-
[3-[(2-chlorophenyl)(4-chlorophenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
-
[3-[(2-chloropyridin-3-yl)(2-methylphenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
-
[3-[(2-chloropyridin-3-yl)(3,4-dichlorophenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
-
[3-[(2-chloropyridin-3-yl)(3-methoxyphenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
-
[3-[(2-chloropyridin-3-yl)(phenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
-
[3-[(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
-
[3-[(3-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
-
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](1,3-dihydro-2H-isoindol-2-yl)methanone
-
-
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](2-hydroxypiperidin-1-yl)methanone
-
-
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](2-methylpiperidin-1-yl)methanone
-
-
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](3,4-dihydroisoquinolin-2(1H)-yl)methanone
-
-
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](3-hydroxypiperidin-1-yl)methanone
-
-
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](3-hydroxypyrrolidin-1-yl)methanone
-
-
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](3-methylpiperidin-1-yl)methanone
-
-
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](4,4-difluoropiperidin-1-yl)methanone
-
-
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](4-fluoropiperidin-1-yl)methanone
-
-
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](4-hydroxypiperidin-1-yl)methanone
-
-
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](4-methylpiperazin-1-yl)methanone
-
-
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](4-methylpiperidin-1-yl)methanone
-
-
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](morpholin-4-yl)methanone
-
-
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
-
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](pyrrolidin-1-yl)methanone
-
-
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl][4-(hydroxymethyl)piperidin-1-yl]methanone
-
-
[3-[(4-chlorophenyl)(2-methylphenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
-
[3-[(6-chloropyridin-3-yl)(2-methylphenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
-
[3-[(S)-(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
-
[3-[1,3-benzodioxol-5-yl(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
-
[3-[phenyl(pyridin-3-yl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
-
[[(E)-[1-[4-(2,5-dimethyl-1H-pyrrol-1-yl)phenyl]ethylidene]amino]oxy](naphthalen-1-ylamino)methanone
-
-
methyl octylphosphonofluoridate
-
-
additional information
-
the microglial-specific isozyme is not inhibited by URB597, i.e. 3'-carbamoyl-biphenyl-3-ylcyclohexylcarbamate, and inhibitors of cyclooxygenases, lipooxygenases, and diacylglycerol lipases, overview
-
additional information
-
fatty acid-derived FAAH inhibitors
-
additional information
-
a series of 5-substituted 7-phenyl-1-(oxazol-2-yl)heptan-1-ones are prepared and evaluated for FAAH inhibitory potency as well as FAAH selectivity versus competitive serine proteases
-
additional information
-
organophosphorus compound-induced FAAH inhibition and the associated anandamide accumulation may lead to reduced limb mobility as a secondary neurotoxic effect
-
additional information
-
analysis of the enzyme inhibition by quantum mechanics/molecular mechanics (QM/MM) modelling
-
additional information
-
synthesis of 18 aryl analogues of anandamide. In vitro evaluation of inhibitory potency, binding to CB1 and CB2 cannabinoid receptors, and potential as metabolic trapping tracers of 4-methoxyphenethyllinoleoylamide and 4-methoxyphenethylarachidonoylamide, overview
-
additional information
-
paracetamol itself does not inhibit FAAH, but undergoes a FAAH-dependent two-step metabolic transformation in the brain, liver, and spinal cord to form the bioactive N-acylphenolamine AM404. Synthesis and evaluation of paracetamol ester enzyme inhibitors, structure-activity relationship studies, overview
-
additional information
-
mechanism of inhibition of fatty acid amide hydrolase by sulfonamide-containing benzothiazoles, long residence time derived from increased kinetic barrier and not exclusively from thermodynamic potency, transition-state analogues, overview
-
additional information
-
a series of oxime carbamates as non-competitive, reversible inhibitors, and show remarkable selectivity for FAAH over the other components of the endocannabinoid system
-
additional information
-
tetra-substituted azetidine ureas with in vivo activity as fatty acid amide hydrolase inhibitors, overview
-
additional information
-
1-(3-biaryloxy-2-oxopropyl)indole-5-carboxylic acids and related compounds can act as dual inhibitors of human cytosolic phospholipase A2alpha, EC 3.1.1.4, and fatty acid amide hydrolase, overview. Substituents at the indole 3- and 5-positions and replacement of the indole scaffold of this compound by other heterocycles strongly influences the inhibitory potency against FAAH
-
additional information
-
1-(3-biaryloxy-2-oxopropyl)indole-5-carboxylic acids and related compounds can act as dual inhibitors of cytosolic phospholipase A2alpha, EC 3.1.1.4, and fatty acid amide hydrolase, overview. Substituents at the indole 3- and 5-positions and replacement of the indole scaffold of this compound by other heterocycles strongly influences the inhibitory potency against FAAH. No inhibition by 1-[3-(biphenyl-2-yloxy)-2-oxopropyl]-1H-indole-5-carboxylic acid, N-methyl-1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-carboxamide, N,N-dimethyl-1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-carboxamide, 1-[5-(morpholin-4-ylcarbonyl)-1H-indol-1-yl]-3-(4-octylphenoxy)propan-2-one, (5E)-5-(4-methoxybenzylidene)-3-[1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indol-5-yl]-1,3-thiazolidine-2,4-dione, 1-[5-(3-benzyl-1,2,4-oxadiazol-5-yl)-1H-indol-1-yl]-3-(4-octylphenoxy)propan-2-one, 1-[5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1H-indol-1-yl]-3-(4-octylphenoxy)propan-2-one, 1-[1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indol-5-yl]-1H-benzimidazole-7-carboxylic acid, and 1-(4-octylphenoxy)-3-[5-(1H-tetrazol-5-yl)-1H-indol-1-yl]propan-2-one at 0.01 mM
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
33
(R)-alpha-methanandamide
-
pH 7.4, 37C
7.94
(S)-alpha-methanandamide
-
pH 7.4, 37C
0.0018
anandamide
-
liver microsomes, pH 7.3, 37C
0.0024
anandamide
-
liver microsomes, pH 7.3, 37C
0.0033
anandamide
-
liver mitochondria, pH 7.3, 37C
0.0123
anandamide
-
recombinant enzyme, pH 7.3, 37C
2.78
anandamide
-
pH 7.4, 37C
2.34
arachidonamide
-
pH 7.4, 37C
0.06
arachidonoyl p-nitroanilide
-
pH 9.0, wild-type enzyme
0.057
decanoyl p-nitroanilide
-
pH 9.0, wild-type enzyme
0.41
heptanoyl p-nitroanilide
-
pH 9.0, wild-type enzyme
0.069
myristoyl p-nitroanilide
-
pH 9.0, mutant enzyme A487V
0.072
myristoyl p-nitroanilide
-
pH 9.0, mutant enzyme I491A
0.092
myristoyl p-nitroanilide
-
pH 9.0, mutant enzyme T488A
0.094
myristoyl p-nitroanilide
-
pH 9.0, mutant enzyme G489A
0.099
myristoyl p-nitroanilide
-
pH 9.0, wild-type enzyme
7.31
N-(o-hydroxyphenyl)arachidonamide
-
pH 7.4, 37C
0.057
nonanoyl p-nitroanilide
-
pH 9.0, mutant enzyme A487V
0.073
nonanoyl p-nitroanilide
-
pH 9.0, mutant enzyme G489A
0.074
nonanoyl p-nitroanilide
-
pH 9.0, wild-type enzyme
0.179
nonanoyl p-nitroanilide
-
pH 9.0, mutant enzyme T488A
0.57
nonanoyl p-nitroanilide
-
pH 9.0, mutant enzyme I491A
0.22
octanoyl p-nitroanilide
-
pH 9.0, wild-type enzyme
0.007
oleamide
-
pH 9.0, mutant enzyme S218A, FAAH protein lacking its N-terminal 39 amino acids is used. This modification removes the predicted N-terminal transmembrane domain of FAAH, the deletion of which is previously found to leave catalytic properties of FAAH unaltered, while at the same time facilitating the purification
0.011
oleamide
-
pH 9.0, wild-type enzyme, FAAH protein lacking its N-terminal 39 amino acids is used. This modification removes the predicted N-terminal transmembrane domain of FAAH, the deletion of which is previously found to leave catalytic properties of FAAH unaltered, while at the same time facilitating the purification
0.012
oleamide
-
pH 9.0, recombinantly expressed FAAH protein lacking the N-terminal transmembrane domain
0.015
oleamide
-
pH 9.0, mutant enzyme H358A, FAAH protein lacking its N-terminal 39 amino acids is used. This modification removes the predicted N-terminal transmembrane domain of FAAH, the deletion of which is previously found to leave catalytic properties of FAAH unaltered, while at the same time facilitating the purification; pH 9.0, mutant enzyme S217A, FAAH protein lacking its N-terminal 39 amino acids is used. This modification removes the predicted N-terminal transmembrane domain of FAAH, the deletion of which is previously found to leave catalytic properties of FAAH unaltered, while at the same time facilitating the purification
0.02
oleamide
-
pH 9.0, mutant enzyme K142A
0.023
oleamide
-
pH 9.0, recombinantly expressed wild-type enzyme
0.029
oleamide
-
pH 9.0, mutant enzyme H449A, FAAH protein lacking its N-terminal 39 amino acids is used. This modification removes the predicted N-terminal transmembrane domain of FAAH , the deletion of which is previously found to leave catalytic properties of FAAH unaltered, while at the same time facilitating the purification
0.03
oleamide
-
pH 9.0, mutant enzyme H184Q, FAAH protein lacking its N-terminal 39 amino acids is used. This modification removes the predicted N-terminal transmembrane domain of FAAH, the deletion of which is previously found to leave catalytic properties of FAAH unaltered, while at the same time facilitating the purification
0.031
oleamide
-
pH 9.0, rat liver FAAH
0.037
oleamide
-
pH 9.0, wild-type enzyme
0.009
oleoyl methyl amide
-
pH 9.0, wild-type enzyme
0.041
oleoyl methyl amide
-
pH 9.0, mutant enzyme K142A
0.022
oleoyl methyl ester
-
pH 9.0, wild-type enzyme
0.032
oleoyl methyl ester
-
pH 9.0, mutant enzyme K142E
0.063
oleoyl methyl ester
-
pH 9.0, mutant enzyme K142A
0.012
oleoyl p-nitroanilide
-
pH 9.0, mutant enzyme K142A
0.021
oleoyl p-nitroanilide
-
pH 9.0, wild-type enzyme
0.074
oleoyl p-nitroanilide
-
pH 9.0, wild-type enzyme
0.083
oleoyl p-nitroanilide
-
pH 9.0, mutant enzyme A487V
0.095
oleoyl p-nitroanilide
-
pH 9.0, mutant enzyme T488A
0.098
oleoyl p-nitroanilide
-
pH 9.0, mutant enzyme G489A
0.126
oleoyl p-nitroanilide
-
pH 9.0, mutant enzyme I491A
0.074
palmitoyl p-nitroanilide
-
pH 9.0, wild-type enzyme
0.065
lauroyl p-nitroanilide
-
pH 9.0, wild-type enzyme
additional information
additional information
-
Michaelis-Menten kinetics, overview
-
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.48
arachidonoyl p-nitroanilide
-
pH 9.0, wild-type enzyme
0.56
decanoyl p-nitroanilide
-
pH 9.0, wild-type enzyme
0.46
heptanoyl p-nitroanilide
-
pH 9.0, wild-type enzyme
0.46
lauroyl p-nitroanilide
-
pH 9.0, wild-type enzyme
0.13
myristoyl p-nitroanilide
-
pH 9.0, mutant enzyme A487V
0.14
myristoyl p-nitroanilide
-
pH 9.0, mutant enzyme G489A
0.19
myristoyl p-nitroanilide
-
pH 9.0, mutant enzyme T488A
0.21
myristoyl p-nitroanilide
-
pH 9.0, mutant enzyme I491A
0.29
myristoyl p-nitroanilide
-
pH 9.0, wild-type enzyme
0.2
nonanoyl p-nitroanilide
-
pH 9.0, mutant enzyme G489A
0.51
nonanoyl p-nitroanilide
-
pH 9.0, mutant enzyme T488A
0.58
nonanoyl p-nitroanilide
-
pH 9.0, mutant enzyme I491A
0.6
nonanoyl p-nitroanilide
-
pH 9.0, mutant enzyme A487V; pH 9.0, wild-type enzyme
0.73
octanoyl p-nitroanilide
-
pH 9.0, wild-type enzyme
0.00026
oleamide
-
pH 9.0, mutant enzyme K142A
0.00064
oleamide
-
pH 9.0, mutant enzyme K142E
0.0022
oleamide
-
pH 9.0, mutant enzyme S217A, FAAH protein lacking its N-terminal 39 amino acids is used. This modification removes the predicted N-terminal transmembrane domain of FAAH, the deletion of which is previously found to leave catalytic properties of FAAH unaltered, while at the same time facilitating the purification
0.055
oleamide
-
pH 9.0, mutant enzyme S218A, FAAH protein lacking its N-terminal 39 amino acids is used. This modification removes the predicted N-terminal transmembrane domain of FAAH, the deletion of which is previously found to leave catalytic properties of FAAH unaltered, while at the same time facilitating the purification
3.3
oleamide
-
pH 9.0, recombinantly expressed FAAH protein lacking the N-terminal transmembrane domain
4.4
oleamide
-
pH 9.0, mutant enzyme H358A, FAAH protein lacking its N-terminal 39 amino acids is used. This modification removes the predicted N-terminal transmembrane domain of FAAH, the deletion of which is previously found to leave catalytic properties of FAAH unaltered, while at the same time facilitating the purification
5.2
oleamide
-
pH 9.0, wild-type enzyme, FAAH protein lacking its N-terminal 39 amino acids is used. This modification removes the predicted N-terminal transmembrane domain of FAAH, the deletion of which is previously found to leave catalytic properties of FAAH unaltered, while at the same time facilitating the purification
7.1
oleamide
-
pH 9.0, recombinantly expressed wild-type enzyme
7.7
oleamide
-
pH 9.0, mutant enzyme H449A, FAAH protein lacking its N-terminal 39 amino acids is used. This modification removes the predicted N-terminal transmembrane domain of FAAH, the deletion of which is previously found to leave catalytic properties of FAAH unaltered, while at the same time facilitating the purification
9
oleamide
-
pH 9.0, wild-type enzyme
20
oleamide
-
pH 9.0, mutant enzyme H184Q, FAAH protein lacking its N-terminal 39 amino acids is used. This modification removes the predicted N-terminal transmembrane domain of FAAH, the deletion of which is previously found to leave catalytic properties of FAAH unaltered, while at the same time facilitating the purification
0.0001
oleoyl methyl amide
-
pH 9.0, mutant enzyme K142A
0.00031
oleoyl methyl amide
-
pH 9.0, mutant enzyme K142E
1.9
oleoyl methyl amide
-
pH 9.0, wild-type enzyme
0.0002
oleoyl methyl ester
-
pH 9.0, mutant enzyme K142E
0.012
oleoyl methyl ester
-
pH 9.0, mutant enzyme K142A
0.17
oleoyl methyl ester
-
pH 9.0, wild-type enzyme
0.00052
oleoyl p-nitroanilide
-
pH 9.0, mutant enzyme K142E
0.15
oleoyl p-nitroanilide
-
pH 9.0, mutant enzyme K142A
0.21
oleoyl p-nitroanilide
-
pH 9.0, mutant enzyme A487V; pH 9.0, mutant enzyme T488A
0.22
oleoyl p-nitroanilide
-
pH 9.0, mutant enzyme I491A
0.25
oleoyl p-nitroanilide
-
pH 9.0, mutant enzyme G489A
0.27
oleoyl p-nitroanilide
-
pH 9.0, wild-type enzyme
2.8
oleoyl p-nitroanilide
-
pH 9.0, wild-type enzyme
0.27
palmitoyl p-nitroanilide
-
pH 9.0, wild-type enzyme
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.000082
(10Z)-1,1,1-trifluorononadec-10-en-2-one
-
-
0.001
(10Z)-1-bromononadec-10-en-2-one
-
-
0.0009
(10Z)-2-oxononadec-10-enamide
-
-
0.000047
(5Z,8Z,11Z,14Z)-1-pyridazin-3-ylicosa-5,8,11,14-tetraen-1-one
-
-
0.000001
(5Z,8Z,11Z,14Z)-1-[1,3]oxazolo[4,5-b]pyridin-2-ylicosa-5,8,11,14-tetraen-1-one
-
-
0.000002
(5Z,8Z,11Z,14Z)-1-[1,3]oxazolo[4,5-c]pyridin-2-ylicosa-5,8,11,14-tetraen-1-one
-
-
0.000018
(5Z,8Z,11Z,14Z)-1-[1,3]oxazolo[5,4-c]pyridin-2-ylicosa-5,8,11,14-tetraen-1-one
-
-
0.00015
(9E)-1-pyridazin-3-yloctadec-9-en-1-one
-
-
0.0000032
(9E)-1-[1,3]oxazolo[4,5-b]pyridin-2-yloctadec-9-en-1-one
-
-
0.00037
(9Z)-1-(1,3-benzoxazol-2-yl)octadec-9-en-1-one
-
-
0.000017
(9Z)-1-(1,3-oxazol-2-yl)octadec-9-en-1-one
-
-
0.0037
(9Z)-1-(1-methyl-1H-tetrazol-5-yl)octadec-9-en-1-one
-
-
0.0098
(9Z)-1-(1H-tetrazol-5-yl)octadec-9-en-1-one
-
-
0.000065
(9Z)-1-(2-methyl-2H-tetrazol-5-yl)octadec-9-en-1-one
-
-
0.0045
(9Z)-1-(4,5-dihydro-1,3-oxazol-2-yl)octadec-9-en-1-one
-
-
0.013
(9Z)-1-(7-methyl-1,3-benzoxazol-2-yl)octadec-9-en-1-one
-
-
0.00054
(9Z)-1-pyrazin-2-yloctadec-9-en-1-one
-
-
0.00013
(9Z)-1-pyridazin-3-yloctadec-9-en-1-one
-
-
0.0025
(9Z)-1-pyrimidin-2-yloctadec-9-en-1-one
-
-
0.00011
(9Z)-1-pyrimidin-4-yloctadec-9-en-1-one
-
-
0.0000023
(9Z)-1-[1,3]oxazolo[4,5-b]pyridin-2-yloctadec-9-en-1-one
-
-
0.0000072
(9Z)-1-[1,3]oxazolo[4,5-c]pyridin-2-yloctadec-9-en-1-one
-
-
0.000011
(9Z)-1-[1,3]oxazolo[5,4-b]pyridin-2-yloctadec-9-en-1-one
-
-
0.0000037
(9Z)-1-[1,3]oxazolo[5,4-c]pyridin-2-yloctadec-9-en-1-one
-
-
0.0085
(9Z)-octadec-9-enal
-
-
0.000038
(phenylamino)[[(E)-[1-[3-(thiophen-2-yl)phenyl]ethylidene]amino]oxy]methanone
-
pH 8.4, 37C
0.0035
1,1'-(5,5'-bi-1,3-oxazole-2,2'-diyl)bis(7-phenylheptan-1-one)
-
-
0.0024
1-(1,3-benzoxazol-2-yl)octadecan-1-one
-
-
0.000048
1-(1,3-oxazol-2-yl)-7-phenylheptan-1-one
-
-
0.000002
1-(5-acetyl-1,3-oxazol-2-yl)-7-phenylheptan-1-one
-
-
0.000003
1-(5-bromo-1,3-oxazol-2-yl)-7-phenylheptan-1-one
-
-
0.000005
1-(5-chloro-1,3-oxazol-2-yl)-7-phenylheptan-1-one
-
-
0.00003
1-(5-fluoro-1,3-oxazol-2-yl)-7-phenylheptan-1-one
-
-
0.000012
1-(5-furan-2-yl-1,3-oxazol-2-yl)-7-phenylheptan-1-one
-
-
0.000003
1-(5-iodo-1,3-oxazol-2-yl)-7-phenylheptan-1-one
-
-
0.00008
1-(5-methyl-1,3-oxazol-2-yl)-7-phenylheptan-1-one
-
-
0.0007
1-pyridazin-3-yloctadecan-1-one
-
-
0.0000069
1-[1,3]oxazolo[4,5-b]pyridin-2-yl-4-phenylbutan-1-one
-
-
0.0000003
1-[1,3]oxazolo[4,5-b]pyridin-2-yl-5-phenylpentan-1-one
-
-
0.0000002
1-[1,3]oxazolo[4,5-b]pyridin-2-yl-6-phenylhexan-1-one
-
-
0.00000028
1-[1,3]oxazolo[4,5-b]pyridin-2-yl-7-phenylheptan-1-one
-
-
0.00000039
1-[1,3]oxazolo[4,5-b]pyridin-2-yl-8-phenyloctan-1-one
-
-
0.00000052
1-[1,3]oxazolo[4,5-b]pyridin-2-yl-9-phenylnonan-1-one
-
-
0.00000015
1-[1,3]oxazolo[4,5-b]pyridin-2-yldec-9-en-1-one
-
-
0.00000018
1-[1,3]oxazolo[4,5-b]pyridin-2-yldec-9-yn-1-one
-
-
0.00000075
1-[1,3]oxazolo[4,5-b]pyridin-2-yldecan-1-one
-
-
0.00000057
1-[1,3]oxazolo[4,5-b]pyridin-2-yldodecan-1-one
-
-
0.0000021
1-[1,3]oxazolo[4,5-b]pyridin-2-ylheptan-1-one
-
-
0.0000019
1-[1,3]oxazolo[4,5-b]pyridin-2-ylhexadecan-1-one
-
-
0.000015
1-[1,3]oxazolo[4,5-b]pyridin-2-ylhexan-1-one
-
-
0.00000014
1-[1,3]oxazolo[4,5-b]pyridin-2-yloctadec-9-yn-1-one
-
-
0.000011
1-[1,3]oxazolo[4,5-b]pyridin-2-yloctadecan-1-one
-
-
0.00000069
1-[1,3]oxazolo[4,5-b]pyridin-2-yloctan-1-one
-
-
0.00005
1-[1,3]oxazolo[4,5-b]pyridin-2-ylpentan-1-one
-
-
0.0000017
1-[1,3]oxazolo[4,5-b]pyridin-2-yltetradecan-1-one
-
-
0.000026
1-[5-(2,4-dimethoxypyrimidin-5-yl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
0.000005
1-[5-(2,6-dimethoxypyrimidin-4-yl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
0.00075
1-[5-(2-aminophenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
0.00011
1-[5-(2-fluorophenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
0.00017
1-[5-(2-hydroxyphenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
0.0004
1-[5-(2-methoxyphenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
0.00013
1-[5-(2-nitrophenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
0.000019
1-[5-(3-aminophenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
0.00005
1-[5-(3-fluorophenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
0.00005
1-[5-(3-hydroxyphenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
0.00004
1-[5-(3-methoxyphenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
0.000015
1-[5-(3-methylpyridin-2-yl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
0.000028
1-[5-(3-nitrophenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
0.00009
1-[5-(4-aminophenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
0.000025
1-[5-(4-aminopyridin-2-yl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
0.000062
1-[5-(4-fluorophenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
0.000002
1-[5-(4-fluoropyridin-2-yl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
0.00014
1-[5-(4-hydroxyphenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
0.0001
1-[5-(4-methoxyphenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
0.0000008
1-[5-(4-methoxypyridin-2-yl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
0.0000006
1-[5-(4-methylpyridin-2-yl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
0.00005
1-[5-(4-nitrophenyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
0.0000032
1-[5-(4-nitropyridin-2-yl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
0.0000028
1-[5-(5-methylpyridin-2-yl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
0.0000033
1-[5-(6-methylpyridin-2-yl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
0.000025
1-[5-(methylsulfanyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
0.000024
1-[5-(morpholin-4-ylcarbonyl)-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
0.00008
1-[5-[(4-methylpiperazin-1-yl)carbonyl]-1,3-oxazol-2-yl]-7-phenylheptan-1-one
-
-
0.000006
2-(7-phenylheptanoyl)-1,3-oxazole-5-carbaldehyde
-
-
0.0000004
2-(7-phenylheptanoyl)-1,3-oxazole-5-carbonitrile
-
-
0.000005
2-(7-phenylheptanoyl)-1,3-oxazole-5-carboxamide
-
-
0.00003
2-(7-phenylheptanoyl)-1,3-oxazole-5-carboxylic acid
-
-
0.0003
2-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzamide
-
-
0.0015
2-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzenesulfonamide
-
-
0.006
2-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzoic acid
-
-
0.00013
2-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzonitrile
-
-
0.0000011
2-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyridine-4-carbonitrile
-
-
0.00005
2-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyridine-4-carboxylic acid
-
-
0.000006
3-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzamide
-
-
0.000002
3-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzenesulfonamide
-
-
0.000005
3-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzoic acid
-
-
0.000015
3-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzonitrile
-
-
0.00016
4-(acetylamino)phenyl 2-(4-[[2-(trifluoromethyl)pyridin-4-yl]amino]phenyl)propanoate
-
pH 7.4, 37C
0.00001
4-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzamide
-
-
0.00001
4-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzenesulfonamide
-
-
0.00006
4-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzoic acid
-
-
0.00004
4-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzonitrile
-
-
0.000015
5-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]furan-2-carboxylic acid
-
-
0.00035
5-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyrimidine-2,4(1H,3H)-dione
-
-
0.000011
5-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]thiophene-2-carboxylic acid
-
-
0.000003
5-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]thiophene-2-sulfonamide
-
-
0.000001
6-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyridine-2-carboxamide
-
-
0.00002
6-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyridine-2-carboxylic acid
-
-
0.0000012
6-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyridine-3-carboxamide
-
-
0.000007
6-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyridine-3-carboxylic acid
-
-
0.000012
6-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyrimidine-2,4(1H,3H)-dione
-
-
0.00008
7-phenyl-1-(5-phenyl-1,3-oxazol-2-yl)heptan-1-one
-
-
0.0000047
7-phenyl-1-(5-pyridin-2-yl-1,3-oxazol-2-yl)heptan-1-one
-
-
0.0000053
7-phenyl-1-(5-pyrimidin-2-yl-1,3-oxazol-2-yl)heptan-1-one
-
-
0.0000023
7-phenyl-1-(5-pyrimidin-4-yl-1,3-oxazol-2-yl)heptan-1-one
-
-
0.000022
7-phenyl-1-(5-pyrimidin-5-yl-1,3-oxazol-2-yl)heptan-1-one
-
-
0.000055
7-phenyl-1-(5-thiophen-2-yl-1,3-oxazol-2-yl)heptan-1-one
-
-
0.000063
7-phenyl-1-[5-(1H-tetrazol-5-yl)-1,3-oxazol-2-yl]heptan-1-one
-
-
0.000008
7-phenyl-1-[5-(piperidin-1-ylcarbonyl)-1,3-oxazol-2-yl]heptan-1-one
-
-
0.00001
7-phenyl-1-[5-(thiomorpholin-4-ylcarbonyl)-1,3-oxazol-2-yl]heptan-1-one
-
-
0.000004
7-phenyl-1-[5-(trifluoroacetyl)-1,3-oxazol-2-yl]heptan-1-one
-
-
0.0000008
7-phenyl-1-[5-(trifluoromethyl)-1,3-oxazol-2-yl]heptan-1-one
-
-
0.005
7-phenyl-1-[5-[2-(trifluoroacetyl)phenyl]-1,3-oxazol-2-yl]heptan-1-one
-
-
0.000016
7-phenyl-1-[5-[3-(trifluoroacetyl)phenyl]-1,3-oxazol-2-yl]heptan-1-one
-
-
0.000065
7-phenyl-1-[5-[4-(trifluoroacetyl)phenyl]-1,3-oxazol-2-yl]heptan-1-one
-
-
0.0000035
7-phenyl-1-[5-[4-(trifluoromethyl)pyridin-2-yl]-1,3-oxazol-2-yl]heptan-1-one
-
-
0.0005
ethyl (10Z)-2-oxononadec-10-enoate
-
-
0.0000009
methyl 2-(7-phenylheptanoyl)-1,3-oxazole-5-carboxylate
-
-
0.00006
methyl 2-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzoate
-
-
0.00013
methyl 2-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyridine-3-carboxylate
-
-
0.0000013
methyl 2-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyridine-4-carboxylate
-
-
0.000012
methyl 3-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzoate
-
-
0.00004
methyl 4-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]benzoate
-
-
0.0000055
methyl 5-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]furan-2-carboxylate
-
-
0.000007
methyl 5-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]thiophene-2-carboxylate
-
-
0.000008
methyl 6-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyridine-2-carboxylate
-
-
0.000002
N,N-dimethyl-2-(7-phenylheptanoyl)-1,3-oxazole-5-carboxamide
-
-
0.0026
N-(4-hydroxy-2-methylphenyl) arachidonoyl amide
-
in the presence of fatty acid-free bovine serum albumin (0.125% w/v). In the absence of fatty acid-free bovine serum albumin, the IC50 value is reduced
0.0021
N-(4-hydroxyphenyl)arachidonylamide
-
in the presence of fatty acid-free bovine serum albumin (0.125% w/v). In the absence of fatty acid-free bovine serum albumin, the IC50 value is reduced
0.000007
N-methyl-2-(7-phenylheptanoyl)-1,3-oxazole-5-carboxamide
-
-
0.0000035
methyl 6-[2-(7-phenylheptanoyl)-1,3-oxazol-5-yl]pyridine-3-carboxylate
-
-
additional information
additional information
-
time-dependent inhibition kinetics with N-[4-(4-methoxy-1,3-benzothiazol-2-yl)phenyl]-1-(thiophen-2-ylsulfonyl)piperidine-4-carboxamide, recombinant enzyme not purified, detailed overview
-
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.000232
(1-benzothiophen-6-ylamino)([(E)-[1-(biphenyl-3-yl)ethylidene]amino]oxy)methanone
-
pH 8.4, 37C
0.000237
(1-benzylpiperidin-4-yl)[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl]methanone
-
pH and temperature not specified in the publication
0.000537
(1-benzylpiperidin-4-yl)[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl]methanone
-
pH and temperature not specified in the publication
0.006
(2R)-oxiran-2-ylmethyl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate
-
37C, substrate: anandamide
0.012
(2S)-oxiran-2-ylmethyl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate
-
37C, substrate: anandamide
0.00037
(4-benzylpiperazin-1-yl)[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl]methanone
-
pH and temperature not specified in the publication
0.00109
(4-benzylpiperazin-1-yl)[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl]methanone
-
pH and temperature not specified in the publication
0.09
(5Z,8Z,11Z,14Z)-N-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)icosa-5,8,11,14-tetraenamide
-
37C, substrate: anandamide
0.069
(5Z,8Z,11Z,14Z)-N-[(2R)-tetrahydrofuran-2-ylmethyl]icosa-5,8,11,14-tetraenamide
-
37C, substrate: anandamide
0.099
(5Z,8Z,11Z,14Z)-N-[(2S)-tetrahydrofuran-2-ylmethyl]icosa-5,8,11,14-tetraenamide
-
37C, substrate: 2-oleoylglycerol
0.000116
(dodecylamino)[[(E)-[1-[3-(thiophen-2-yl)phenyl]ethylidene]amino]oxy]methanone
-
pH 8.4, 37C
0.05
(phenylamino)[[(4-phenylcyclohexylidene)amino]oxy]methanone
-
pH 8.4, 37C
0.000008
(phenylamino)[[(E)-[1-[3-(thiophen-2-yl)phenyl]ethylidene]amino]oxy]methanone
-
pH 8.4, 37C
0.0002
(phenylamino)[[(E)-[1-[4-(thiophen-2-yl)phenyl]ethylidene]amino]oxy]methanone
-
pH 8.4, 37C
0.26
(R,S)-ibuprofen
-
pH 7.4, 37C
0.001
([(E)-[1-(2,2'-bithiophen-5-yl)ethylidene]amino]oxy)(naphthalen-1-ylamino)methanone
-
pH 8.4, 37C
0.001
([(E)-[1-(4-cyclohexylphenyl)ethylidene]amino]oxy)(naphthalen-1-ylamino)methanone
-
pH 8.4, 37C
0.05
([(E)-[1-(biphenyl-3-yl)ethylidene]amino]oxy)(diphenylamino)methanone
-
pH 8.4, 37C
0.00001
([(E)-[1-(biphenyl-3-yl)ethylidene]amino]oxy)(naphthalen-1-ylamino)methanone
-
pH 8.4, 37C
0.000069
([(E)-[1-(biphenyl-3-yl)ethylidene]amino]oxy)(phenylamino)methanone
-
pH 8.4, 37C
0.00022
([(E)-[1-(biphenyl-3-yl)ethylidene]amino]oxy)(piperidin-1-yl)methanone
-
pH 8.4, 37C
0.000017
([(E)-[1-(biphenyl-3-yl)ethylidene]amino]oxy)[(4-fluorophenyl)amino]methanone
-
pH 8.4, 37C
0.000028
([(E)-[1-(biphenyl-3-yl)ethylidene]amino]oxy)[(4-methoxyphenyl)amino]methanone
-
pH 8.4, 37C
0.0001
([(E)-[1-(biphenyl-3-yl)ethylidene]amino]oxy)[(5-phenylpentyl)amino]methanone
-
pH 8.4, 37C
0.05
([(E)-[1-(biphenyl-4-yl)ethylidene]amino]oxy)(dimethylamino)methanone
-
pH 8.4, 37C
0.000401
([(E)-[1-(biphenyl-4-yl)ethylidene]amino]oxy)(naphthalen-1-ylamino)methanone
-
pH 8.4, 37C
0.00076
([(E)-[1-(biphenyl-4-yl)ethylidene]amino]oxy)(phenylamino)methanone
-
pH 8.4, 37C
0.091
1,3-benzodioxol-5-ylmethyl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate
-
37C, substrate: anandamide
0.0051
1-(2-oxo-3-[[4'-(propan-2-yl)biphenyl-4-yl]oxy]propyl)-1H-indole-5-carboxylic acid
-
pH and temperature not specified in the publication
0.000006
1-([1,3]oxazolo[4,5-b]pyridin-2-yl)-6-phenylhexan-1-one
-
pH and temperature not specified in the publication
0.000028
1-[(3S)-1-[4-(1-benzofuran-2-yl)pyrimidin-2-yl]piperidin-3-yl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one
-
pH and temperature not specified in the publication
0.0001
1-[(3S)-1-[4-(1-benzofuran-2-yl)pyrimidin-2-yl]piperidin-3-yl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one
-
pH and temperature not specified in the publication
0.0012
1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indole-5-carboxylic acid
-
pH and temperature not specified in the publication
0.0017
1-[2-oxo-3-[4-(2-phenoxyethoxy)phenoxy]propyl]-1H-indole-5-carboxylic acid
-
pH and temperature not specified in the publication
0.0029
1-[2-oxo-3-[4-(2-phenylpropan-2-yl)phenoxy]propyl]-1H-indole-5-carboxylic acid
-
pH and temperature not specified in the publication
0.0019
1-[3-(4-benzylphenoxy)-2-oxopropyl]-1H-indole-5-carboxylic acid
-
pH and temperature not specified in the publication
0.00016
1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indazole-5-carboxylic acid
-
pH and temperature not specified in the publication
0.0064
1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-carboxamide
-
pH and temperature not specified in the publication
0.0023
1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-carboxylic acid
-
pH and temperature not specified in the publication
0.0016
1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-sulfonamide
-
pH and temperature not specified in the publication
0.0034
1-[3-(biphenyl-3-yloxy)-2-oxopropyl]-1H-indole-5-carboxylic acid
-
pH and temperature not specified in the publication
0.00046
1-[3-(biphenyl-4-yloxy)-2-oxopropyl]-1H-indole-5-carboxylic acid
-
pH and temperature not specified in the publication
0.00023
1-[3-[(3'-chlorobiphenyl-4-yl)oxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
pH and temperature not specified in the publication
0.00025
1-[3-[(3'-fluorobiphenyl-4-yl)oxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
pH and temperature not specified in the publication
0.005
1-[3-[(3-chlorobiphenyl-4-yl)oxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
pH and temperature not specified in the publication
0.00059
1-[3-[(3-fluorobiphenyl-4-yl)oxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
pH and temperature not specified in the publication
0.0074
1-[3-[(3-methoxybiphenyl-4-yl)oxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
pH and temperature not specified in the publication
0.000464
1-[3-[(4'-chlorobiphenyl-4-yl)oxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
pH and temperature not specified in the publication
0.00053
1-[3-[(4'-chlorobiphenyl-4-yl)oxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
pH and temperature not specified in the publication
0.00503
1-[3-[(4'-chlorobiphenyl-4-yl)oxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
pH and temperature not specified in the publication
0.00024
1-[3-[(4'-fluorobiphenyl-4-yl)oxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
pH and temperature not specified in the publication
0.00053
1-[3-[(4'-methoxybiphenyl-4-yl)oxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
pH and temperature not specified in the publication
0.00058
1-[3-[(4'-methylbiphenyl-4-yl)oxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
pH and temperature not specified in the publication
0.00009
1-[3-[4-(4-fluorophenyl)phenoxy]-2-oxopropyl]indazole-5-carboxylic acid
-
pH and temperature not specified in the publication
0.0026
1-[3-[4-(decyloxy)phenoxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
pH and temperature not specified in the publication
0.0034
1-[3-[4-(heptyloxy)phenoxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
pH and temperature not specified in the publication
0.0035
1-[3-[4-(hexyloxy)phenoxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
pH and temperature not specified in the publication
0.0018
1-[3-[4-(nonyloxy)phenoxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
pH and temperature not specified in the publication
0.0022
1-[3-[4-(octyloxy)phenoxy]-2-oxopropyl]-1H-indole-5-carboxylic acid
-
pH and temperature not specified in the publication
0.098
2,2-dimethyl-1,3-dioxolan-4-ylmethyl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate
-
37C, substrate: anandamide
0.021
2-(5,5-dimethyl-1,3-dioxan-2-yl)ethyl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate
-
37C, substrate: anandamide
0.099
2-(5,5-dimethyl-1,3-dioxan-2-yl)ethyl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate
-
37C, substrate: 2-oleoylglycerol
0.00022
3'-carbamoylbiphenyl-3-yl cyclohexylcarbamate
-
pH and temperature not specified in the publication
0.00000038
3'-carbamoylbiphenyl-3-yl undec-10-yn-1-ylcarbamate
-
pH 9.0, 37C
0.000084
3'-[(1E)-N-[(phenylcarbamoyl)oxy]ethanimidoyl]biphenyl-3-carboxamide
-
pH 8.4, 37C
0.00531
3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N,N-diethylazetidine-1-carboxamide
-
pH and temperature not specified in the publication
0.0624
3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N,N-diethylazetidine-1-carboxamide
-
pH and temperature not specified in the publication
0.0297
3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-ethyl-N-(2-hydroxyethyl)azetidine-1-carboxamide
-
pH and temperature not specified in the publication
0.5
3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-ethyl-N-(2-hydroxyethyl)azetidine-1-carboxamide
-
above, pH and temperature not specified in the publication
0.000681
3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-methyl-N-(2-phenylethyl)azetidine-1-carboxamide
-
pH and temperature not specified in the publication
0.00654
3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-methyl-N-(2-phenylethyl)azetidine-1-carboxamide
-
pH and temperature not specified in the publication
0.14
3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-methyl-N-phenylazetidine-1-carboxamide
-
pH and temperature not specified in the publication
0.193
3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-methyl-N-phenylazetidine-1-carboxamide
-
pH and temperature not specified in the publication
0.00001
4-(3-phenyl-[1,2,4]thiadiazol-5-yl)piperazine-1-carboxylic acid phenylamide
-
JNJ-1661010, without preincubation
0.000012
4-(3-phenyl-[1,2,4]thiadiazol-5-yl)piperazine-1-carboxylic acid phenylamide
-
JNJ-1661010, without preincubation
0.00018
4-(acetylamino)phenyl (4-[[2-(trifluoromethyl)pyridin-4-yl]amino]phenyl)acetate
-
pH 7.4, 37C
0.0001
4-(acetylamino)phenyl 2-(4-[[2-(trifluoromethyl)pyridin-4-yl]amino]phenyl)propanoate
-
pH 7.4, 37C
0.058
4-(acetylamino)phenyl 2-[[2-(trifluoromethyl)pyridin-4-yl]amino]pyridine-3-carboxylate
-
pH 7.4, 37C
0.0087
4-(acetylamino)phenyl 2-[[3-(trifluoromethyl)phenyl]amino]benzoate
-
pH 7.4, 37C
0.3
4-(acetylamino)phenyl 2-[[3-(trifluoromethyl)phenyl]amino]pyridine-3-carboxylate
-
above, pH 7.4, 37C
0.064
4-(acetylamino)phenyl 2-{[2-(trifluoromethyl)pyridin-4-yl]amino}benzoate
-
pH 7.4, 37C
0.0015
4-(acetylamino)phenyl 3-(4-[[2-(trifluoromethyl)pyridin-4-yl]amino]phenyl)propanoate
-
pH 7.4, 37C
0.0046
4-(acetylamino)phenyl 3-methyl-4-[[2-(trifluoromethyl)pyridin-4-yl]amino]benzoate
-
pH 7.4, 37C
0.047
4-(acetylamino)phenyl 3-[[2-(trifluoromethyl)pyridin-4-yl]amino]benzoate
-
pH 7.4, 37C
0.022
4-(acetylamino)phenyl 4-([[2-(trifluoromethyl)pyridin-4-yl]amino]methyl)benzoate
-
pH 7.4, 37C
0.031
4-(acetylamino)phenyl 4-chloro-2-[[2-(trifluoromethyl)pyridin-4-yl]amino]benzoate
-
pH 7.4, 37C
0.0027
4-(acetylamino)phenyl 4-[[2-(trifluoromethyl)pyridin-4-yl]amino]benzoate
-
pH 7.4, 37C
0.0043
4-(acetylamino)phenyl 5-chloro-2-[[2-(trifluoromethyl)pyridin-4-yl]amino]benzoate
-
pH 7.4, 37C
0.038
4-(acetylamino)phenyl 5-methyl-2-[[2-(trifluoromethyl)pyridin-4-yl]amino]benzoate
-
pH 7.4, 37C
0.003
4-(acetylamino)phenyl N-(3-methyl-4-[[2-(trifluoromethyl)pyridin-4-yl]amino]benzoyl)glycinate
-
pH 7.4, 37C
0.00087
4-(acetylamino)phenyl N-(4-[[2-(trifluoromethyl)pyridin-4-yl]amino]benzoyl)glycinate
-
pH 7.4, 37C
0.0026
4-(acetylamino)phenyl N-[(4-[[2-(trifluoromethyl)pyridin-4-yl]amino]phenyl)acetyl]glycinate
-
pH 7.4, 37C
0.00073
4-(acetylamino)phenyl N-[2-(4-[[2-(trifluoromethyl)pyridin-4-yl]amino]phenyl)propanoyl]glycinate
-
pH 7.4, 37C
0.000283
4-(benzyloxy)phenyl butylcarbamate
-
pH 9.0, 37C
0.000053
4-[3-[4-(decyloxy)phenoxy]-2-oxopropoxy]benzoic acid
-
pH and temperature not specified in the publication
0.000005
6-bromo-N-(2-fluorophenyl)-1'H,4H-spiro[1,3-benzodioxine-2,4'-piperidine]-1'-carboxamide
-
pH and temperature not specified in the publication
0.000036
6-bromo-N-(2-fluorophenyl)-1'H,4H-spiro[1,3-benzodioxine-2,4'-piperidine]-1'-carboxamide
-
pH and temperature not specified in the publication
0.000206
7-phenyl-1-(5-pyridin-2-yl-1,3-oxazol-2-yl)heptan-1-one
-
pH 9.0, 37C
0.000647
azepan-1-yl[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl]methanone
-
pH and temperature not specified in the publication
0.0111
azepan-1-yl[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl]methanone
-
pH and temperature not specified in the publication
0.00263
azetidin-1-yl[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl]methanone
-
pH and temperature not specified in the publication
0.0988
azetidin-1-yl[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl]methanone
-
pH and temperature not specified in the publication
0.011
benzol
-
-
0.00004
chlorpyrifos oxon
-
-
0.00004
chlorpyrifos oxon
-
25C, pH 9.0, brain enzyme
0.000056
chlorpyrifos oxon
-
25C, pH 9.0, liver enzyme
0.0000012
decyl benzodioxaphosphorin oxide
-
-
0.029
DFP
-
25C, pH 9.0, liver enzyme
0.048
DFP
-
25C, pH 9.0, brain enzyme
0.009
diazoxon
-
-
0.0018
dichlorvos
-
-
0.048
diisopropyl fluorophosphate
-
-
0.0000005
dodecyl benzodioxaphosphorin oxide
-
-
0.000002
dodecyl sulfonyl fluoride
-
-
0.0000009
dodecyl-benzodioxaphosphorin oxide
-
25C, pH 9.0, liver enzyme
0.000005
dodecyl-benzodioxaphosphorin oxide
-
25C, pH 9.0, brain enzyme
0.0000006
ethyl octylphosphonofluoridate
-
-
0.0000006
ethyl octylphosphonofluoridate
-
25C, pH 9.0, brain enzyme
0.0000011
ethyl octylphosphonofluoridate
-
25C, pH 9.0, liver enzyme
0.000126
heptyl benzodioxaphosphorin oxide
-
-
0.000002
isopropyl dodecylfluorophosphate
-
-
0.000001
JP104
-
pH 9.0, 37C
0.000025
methyl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraen-1-ylphosphonofluoridate
-
pH and temperature not specified in the publication
0.0000001
methyl arachidonyl phosphonofluoridate
-
25C, pH 9.0, brain enzyme
0.000082
methyl arachidonyl phosphonofluoridate
-
25C, pH 9.0, liver enzyme
0.0000001
methyl arachidonylfluoroposphate
-
-
0.00541
N,N-dibenzyl-3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidine-1-carboxamide
-
pH and temperature not specified in the publication
0.5
N,N-dibenzyl-3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidine-1-carboxamide
-
above, pH and temperature not specified in the publication
0.00053
N,N-dimethyl-1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-sulfonamide
-
pH and temperature not specified in the publication
0.0013
N-(3-methylpyridin-2-yl)-2-(4'-isobutylphenyl)propionamide
-
pH 7.4, 37C
0.025
N-(phenylcarbamoyl)-3'-[(1E)-N-[(phenylcarbamoyl)oxy]ethanimidoyl]biphenyl-3-carboxamide
-
pH 8.4, 37C
0.5
N-benzyl-3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-(2-hydroxyethyl)azetidine-1-carboxamide
-
above, pH and temperature not specified in the publication
0.00209
N-benzyl-3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-methylazetidine-1-carboxamide
-
pH and temperature not specified in the publication
0.242
N-benzyl-3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-methylazetidine-1-carboxamide
-
pH and temperature not specified in the publication
0.5
N-benzyl-3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-[2-(dimethylamino)ethyl]azetidine-1-carboxamide
-
above, pH and temperature not specified in the publication
0.0115
N-benzyl-3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidine-1-carboxamide
-
pH and temperature not specified in the publication
0.5
N-benzyl-3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidine-1-carboxamide
-
above, pH and temperature not specified in the publication
0.000094
N-benzyl-3-[(R)-(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-methylazetidine-1-carboxamide
-
pH and temperature not specified in the publication
0.887
N-benzyl-3-[(R)-(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-methylazetidine-1-carboxamide
-
pH and temperature not specified in the publication
0.00453
N-benzyl-3-[(S)-(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-methylazetidine-1-carboxamide
-
pH and temperature not specified in the publication
0.0408
N-benzyl-3-[(S)-(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]-N-methylazetidine-1-carboxamide
-
pH and temperature not specified in the publication
0.00075
N-methyl-1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-sulfonamide
-
pH and temperature not specified in the publication
0.000064
N-n-heptyl benzodioxaphosphorin oxide
-
-
0.5
N-tert-butyl-3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidine-1-carboxamide
-
above, pH and temperature not specified in the publication
0.000002
N-[4-(4-methoxy-1,3-benzothiazol-2-yl)phenyl]-1-(thiophen-2-ylsulfonyl)piperidine-4-carboxamide
-
pH 8.0, 22C, at 78 nM substrate anandamide
0.0000038
N-[4-(4-methoxy-1,3-benzothiazol-2-yl)phenyl]-1-(thiophen-2-ylsulfonyl)piperidine-4-carboxamide
-
pH 8.0, 22C, at 0.01 mM substrate anandamide
0.0000051
N-[4-(4-methoxy-1,3-benzothiazol-2-yl)phenyl]-1-(thiophen-2-ylsulfonyl)piperidine-4-carboxamide
-
pH 8.0, 22C, at 0.005 mM substrate anandamide
0.000073
O-n-octyl benzodioxaphosphorin oxide
-
-
0.000024
O-octyl-benzodioxaphosphorin oxide
-
25C, pH 9.0, liver enzyme
0.000073
O-octyl-benzodioxaphosphorin oxide
-
25C, pH 9.0, brain enzyme
0.000019
octyl sulfonyl fluoride
-
-
0.000007
octyl-benzodioxaphosphorin oxide
-
25C, pH 9.0, liver enzyme
0.0000081
octyl-benzodioxaphosphorin oxide
-
25C, pH 9.0, brain enzyme
0.0000134
OL-135
-
pH 9.0, 37C
0.000016
OL-135
-
pH and temperature not specified in the publication
0.000025
OL-135
-
pH and temperature not specified in the publication
0.0000243
oleoyl oxazolopyridine
-
recombinant enzyme, pH 7.3, 37C
-
0.00000018
oleyl-benzodioxaphosphorin oxide
-
25C, pH 9.0, liver enzyme
0.00000067
oleyl-benzodioxaphosphorin oxide
-
25C, pH 9.0, brain enzyme
0.012
oxiran-2-ylmethyl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate
-
37C, substrate: anandamide
0.019
oxiran-2-ylmethyl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate
-
37C, substrate: 2-oleoylglycerol
0.0082
oxiran-2-ylmethyl (9Z)-hexadec-9-enoate
-
37C, substrate: anandamide
0.028
oxiran-2-ylmethyl (9Z)-hexadec-9-enoate
-
37C, substrate: 2-oleoylglycerol
0.011
oxiran-2-ylmethyl (9Z)-octadec-9-enoate
-
37C, substrate: anandamide
0.0016
oxiran-2-ylmethyl (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
-
37C, substrate: anandamide
0.05
oxiran-2-ylmethyl (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
-
37C, substrate: 2-oleoylglycerol
0.061
oxiran-2-ylmethyl 1,1'-biphenyl-3-carboxylate
-
37C, substrate: anandamide
0.035
oxiran-2-ylmethyl 1,1'-biphenyl-4-carboxylate
-
37C, substrate: anandamide
0.00054
Paraoxon
-
-
0.00054
Paraoxon
-
25C, pH 9.0, brain enzyme
0.00077
Paraoxon
-
25C, pH 9.0, liver enzyme
0.0089
phenyl-benzodioxaphosphorin oxide
-
25C, pH 9.0, liver enzyme
0.011
phenyl-benzodioxaphosphorin oxide
-
25C, pH 9.0, brain enzyme
0.000112
piperidin-1-yl[[(E)-[1-[3-(thiophen-2-yl)phenyl]ethylidene]amino]oxy]methanone
-
pH 8.4, 37C
0.00015
profenofos
-
25C, pH 9.0, liver enzyme
0.00027
profenofos
-
25C, pH 9.0, brain enzyme
0.0000017
S-heptyl benzodioxaphosphorin oxide
-
-
0.00000015
S-nonyl benzodioxaphosphorin oxide
-
-
0.0000057
S-pentyl benzodioxaphosphorin oxide
-
-
0.000131
stearyl benzodioxaphosphorin oxide
-
-
0.026
tetrahydro-2H-pyran-2-ylmethyl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate
-
37C, substrate: 2-oleoylglycerol
0.051
tetrahydro-2H-pyran-2-ylmethyl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate
-
37C, substrate: anandamide
0.029
tetrahydro-2H-pyran-2-ylmethyl (9Z)-octadec-9-enoate
-
37C, substrate: anandamide
0.0075
tetrahydro-2H-pyran-2-ylmethyl (9Z,12Z)-octadeca-9,12-dienoate
-
37C, substrate: anandamide
0.019
tetrahydro-2H-pyran-2-ylmethyl (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
-
37C, substrate: anandamide
0.043
tetrahydro-2H-pyran-2-ylmethyl 1,1'-biphenyl-2-carboxylate
-
37C, substrate: anandamide
0.018
tetrahydro-2H-pyran-2-ylmethyl 1,1'-biphenyl-3-carboxylate
-
37C, substrate: anandamide
0.032
tetrahydro-2H-pyran-2-ylmethyl 1,1'-biphenyl-4-carboxylate
-
37C, substrate: anandamide
0.08
tetrahydro-2H-pyran-2-ylmethyl 1,1'-biphenyl-4-carboxylate
-
37C, substrate: 2-oleoylglycerol
0.053
tetrahydro-2H-pyran-2-ylmethyl benzoate
-
37C, substrate: anandamide
0.000063
URB524
P97612
pH and temperature not specified in the publication
-
0.00136
URB532
-
pH 9.0, 37C
0.000003
URB597
-
pH and temperature not specified in the publication
0.000004
URB597
-
pH and temperature not specified in the publication
0.0000046
URB597
P97612
pH and temperature not specified in the publication
0.028
[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate
-
37C, substrate: anandamide
0.017
[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate
-
37C, substrate: anandamide
0.132
[3-[(2-chlorophenyl)(4-chlorophenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
above, pH and temperature not specified in the publication
0.5
[3-[(2-chlorophenyl)(4-chlorophenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
above, pH and temperature not specified in the publication
0.0184
[3-[(2-chloropyridin-3-yl)(2-methylphenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.206
[3-[(2-chloropyridin-3-yl)(2-methylphenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.000471
[3-[(2-chloropyridin-3-yl)(3,4-dichlorophenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.00669
[3-[(2-chloropyridin-3-yl)(3,4-dichlorophenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.000713
[3-[(2-chloropyridin-3-yl)(3-methoxyphenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.00717
[3-[(2-chloropyridin-3-yl)(3-methoxyphenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.000556
[3-[(2-chloropyridin-3-yl)(phenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.00739
[3-[(2-chloropyridin-3-yl)(phenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.00542
[3-[(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.0366
[3-[(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.000375
[3-[(3-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.00501
[3-[(3-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.00399
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](1,3-dihydro-2H-isoindol-2-yl)methanone
-
pH and temperature not specified in the publication
0.0247
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](1,3-dihydro-2H-isoindol-2-yl)methanone
-
pH and temperature not specified in the publication
0.5
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](2-hydroxypiperidin-1-yl)methanone
-
above, pH and temperature not specified in the publication
0.000505
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](2-methylpiperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.00504
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](2-methylpiperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.00682
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](3,4-dihydroisoquinolin-2(1H)-yl)methanone
-
pH and temperature not specified in the publication
0.531
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](3,4-dihydroisoquinolin-2(1H)-yl)methanone
-
pH and temperature not specified in the publication
0.00524
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](3-hydroxypiperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.135
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](3-hydroxypiperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.124
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](3-hydroxypyrrolidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.5
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](3-hydroxypyrrolidin-1-yl)methanone
-
above, pH and temperature not specified in the publication
0.000161
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](3-methylpiperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.0164
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](3-methylpiperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.000854
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](4,4-difluoropiperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.0051
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](4,4-difluoropiperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.000388
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](4-fluoropiperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.00225
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](4-fluoropiperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.00288
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](4-hydroxypiperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.037
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](4-hydroxypiperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.00458
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](4-methylpiperazin-1-yl)methanone
-
pH and temperature not specified in the publication
0.0286
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](4-methylpiperazin-1-yl)methanone
-
pH and temperature not specified in the publication
0.000126
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](4-methylpiperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.000423
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](4-methylpiperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.00248
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](morpholin-4-yl)methanone
-
pH and temperature not specified in the publication
0.0279
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](morpholin-4-yl)methanone
-
pH and temperature not specified in the publication
0.000447
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.00312
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](pyrrolidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.0705
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](pyrrolidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.00148
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl][4-(hydroxymethyl)piperidin-1-yl]methanone
-
pH and temperature not specified in the publication
0.0174
[3-[(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl][4-(hydroxymethyl)piperidin-1-yl]methanone
-
pH and temperature not specified in the publication
0.000937
[3-[(4-chlorophenyl)(2-methylphenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.0096
[3-[(4-chlorophenyl)(2-methylphenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.5
[3-[(6-chloropyridin-3-yl)(2-methylphenyl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
above, pH and temperature not specified in the publication
0.042
[3-[(S)-(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.5
[3-[(S)-(4-chlorophenyl)(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
above, pH and temperature not specified in the publication
0.000413
[3-[1,3-benzodioxol-5-yl(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.00332
[3-[1,3-benzodioxol-5-yl(2-chloropyridin-3-yl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.000715
[3-[phenyl(pyridin-3-yl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.00364
[3-[phenyl(pyridin-3-yl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.00809
[3-[phenyl(pyridin-3-yl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.0829
[3-[phenyl(pyridin-3-yl)methoxy]azetidin-1-yl](piperidin-1-yl)methanone
-
pH and temperature not specified in the publication
0.001
[[(E)-[1-[4-(2,5-dimethyl-1H-pyrrol-1-yl)phenyl]ethylidene]amino]oxy](naphthalen-1-ylamino)methanone
-
pH 8.4, 37C
0.00000079
methyl octylphosphonofluoridate
-
-
additional information
additional information
-
pIC50, i.e. -log IC50. values of anadamide analogue inhibitors, overview
-
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
7.4
-
assay at
7.6
-
assay at
8
-
assay at
8.4
-
assay at
9
-
assay at
9.5
-
native and recombinant enzymes
pH RANGE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
additional information
-
pH rate profiles of FAAH mutants
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
22
-
assay at room temperature
37
-
assay at
37
-
assay at
37
-
assay at
37
-
assay at
37
-
assay at
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
-
very little expression
Manually annotated by BRENDA team
-
temporal changes in mouse brain fatty acid amide hydrolase activity, determination by ex vivo autoradiography, overview
Manually annotated by BRENDA team
Rattus norvegicus Sprague-Dawley
-
-
-
Manually annotated by BRENDA team
-
role of FAAH in epithelial cells of the choroid plexus may be to control the concentration of oleamide in the cerebrospinal fluid. FAAH may exert an important regulatory role in shaping the duration and magnitude of the sleep-inducing effect of endogenously or exogenously derived oleamide
Manually annotated by BRENDA team
-
highly expressed
Manually annotated by BRENDA team
Mus musculus C57BL/6J
-
-
-
Manually annotated by BRENDA team
-
primary sensory, FAAH is localized in the soma, in small dorsal root ganglion neurons
Manually annotated by BRENDA team
-
expression of cannabinoid receptor type 1 and fatty acid amide hydrolase throughout the retina, from the foveal pit to the far periphery, and are present in the photoreceptor, outer plexiform, inner nuclear, inner plexiform, and retinal ganglion cell layers, most prominent CB1R and FAAH expression in cone synaptic terminals and in the ganglion cell layer
Manually annotated by BRENDA team
-
full-wall bladder and mucosa, urothelium, no FAAH immunoreactivity in other structures of the bladder
Manually annotated by BRENDA team
-
mucosa, urothelium, no FAAH immunoreactivity in other structures of the bladder
Manually annotated by BRENDA team
Rattus norvegicus Sprague-Dawley
-
mucosa, urothelium, no FAAH immunoreactivity in other structures of the bladder
-
Manually annotated by BRENDA team
Rattus norvegicus Sprague-Dawley
-
-
-
Manually annotated by BRENDA team
additional information
-
no activity in brain, small intestine and testis, no activity in heart
Manually annotated by BRENDA team
additional information
-
not in human HeLa epithelioid carcinoma. Human HMC-1 mast cells show FAAH activity only when 5-lipoxygenase activity is inhibited
Manually annotated by BRENDA team
additional information
-
culturing does not induce major changes in FAAH expression in primary sensory neurons
Manually annotated by BRENDA team
additional information
-
determination of the expression patterns of the cannabinoid receptor type 1 and the fatty acid amide hydrolase in the nervous system, triple-labeling immunofluorescence and confocal microscopy analysis, overview. Neither CB1R nor FAAH are found in the retinal glia, the Mller cells
Manually annotated by BRENDA team
additional information
-
negligible activity in brown adipose tissue and heart
Manually annotated by BRENDA team
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY
GeneOntology No.
LITERATURE
SOURCE
-
FAAH-2, localization of FAAH-2 on the cytoplasmic face of lipid droplets, lipid droplet localization is essential for FAAH-2
-
Manually annotated by BRENDA team
-
integral membrane protein
Manually annotated by BRENDA team
-
integral membrane protein
Manually annotated by BRENDA team
-
integral membrane enzyme
Manually annotated by BRENDA team
-
FAAH-2 is luminally orientated in the membrane, FAAH-1 shows a predominantly cytoplasmic orientation in the membrane
Manually annotated by BRENDA team
-
bound to intracellular membranes, mainly of the endoplasmic reticulum
Manually annotated by BRENDA team
additional information
-
no activity in cytosol
-
Manually annotated by BRENDA team
additional information
-
FAAH-2 is not translocated into the endoplasmic reticulum lumen
-
Manually annotated by BRENDA team
SUBUNITS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
?
-
x * 63000, about, SDS-PAGE
oligomer
-
wild-type FAAH behaves as a larger oligomer than FAAH protein lacking the N-terminal transmembrane domain. Presence of SDS-resistant oligomers for wild-type FAAH, but not for FAAH protein lacking the N-terminal transmembrane domain. Self-association through the transmembrane domain is demonstrated
?
Rattus norvegicus Sprague-Dawley
-
x * 63000, about, SDS-PAGE
-
additional information
-
three major cavities in the active site are the membrane access channel, the acyl-chain binding pocket, and the cytosolic port, overview. The core structure of the FAAH monomer adopts an alpha/beta fold with a twisted 11-strand beta-sheet in the center and 24 alpha-helices surrounding the sheet
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
glycoprotein
-
FAAH is N-glycosylated
no glycoprotein
-
FAAH-2 does not undergo N-glycosylation
glycoprotein
-
contains N-linked glycans
Crystallization/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
purified recombinant His-tagged apo FAAH, hanging drop vapor diffusion method, X-ray diffraction structure determination and analysis at 2.9 A resolution, molecular replacement
-
2.8 A crystal structure
-
purified recombinant His-tagged apo FAAH, hanging drop vapor diffusion method, X-ray diffraction structure determination and analysis at 2.9 A resolution, molecular replacement
-
recombinant fatty acid amide hydrolase mutant L192F/F194Y/A377T/S435N/I491V/V495M bound to carbamate inhibitor URB597 or inhibitor PF-3845, 25-30 mg/ml protein in 10 mM HEPES, pH 7.0, 500 mM NaCl, 2 mM dithiothreitol, and 0.08% n-undecyl-beta-D-maltoside or 0.1% n-decyl-beta-D-maltoside for inhibitor URB597-enzyme or PF-3845-enzyme conjugate, respectively, supplementation of the FAAHURB597 proteinsample with 1.6% benzyldimethyl(2-dodecyloxyethyl)-ammonium chloride and mixed at a 1:1 proportion with a crystallization buffer containing 30% PEG 400, 100 mM TrisHCl pH 7.5, and 100 mM MgCl2, supplementation of the FAAHPF-3845 protein sample with 1.6% benzyl-dimethyl-dodecyl ammonium bromide and mixed at a 1:1 ratio with a crystallization buffer containing 30% PEG 400, 100 mM 2-(N-morpholino)ethanesulfonate/NaOH, pH 5.5, and 400 mM LiCl, sitting drop vapor diffusion at 14C, X-ray diffraction structure determination and analysis at 2.3 A resolution
P97612
pH STABILITY
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
5
-
not stable below
692951
GENERAL STABILITY
ORGANISM
UNIPROT
LITERATURE
100 mM Na2CO3 incubation (30 min at 4 C and pH 11.0) destroys the catalytic activity of both wild-type FAAH and FAAH protein lacking the N-terminal transmembrane domain derived from transfected COS-7 cells, whereas the native liver-isolated FAAH is stable to this treatment
-
Purification/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
recombinant His-tagged FAAH from Escherichia coli strain by nickel affinity chromatography
-
all Escherichia coli expression constructs contained a deletion of the N-terminal transmembrane domain of FAAH. Deletion of this region facilitates its purification from Escherichia coli but had no effect on the enzymatic activity of FAAH
-
recombinant His-tagged FAAH from Escherichia coli strain by nickel affinity chromatography
-
recombinantly expressed wild-type FAAH and FAAH protein lacking the N-terminal transmembrane domain
-
Cloned/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
transcriptional profiling of flowering-related genes in wild-type and FAAH overexpressing and knockout plants, overview
Q7XJJ7
expressed in COS-7
-
expression of His-tagged FAAH in Escherichia coli strain
-
FLAG-tagged FAAH and FAAH-2 expression in HeLa and COS-7 cells, analysis of subcellular localization of full-length and truncated enzymes in transfected cells, overview
-
stable expression of FAAH in CHO cells
-
expressed in COS-7
-
expression in COS-7 cells
-
expression of His-tagged FAAH in Escherichia coli strain
-
expression of humanized rat FAAH
-
expression of mutant L192F/F194Y/A377T/S435N/I491V/V495M in Escherichia coli strain BL21
P97612
FAAH is cloned from rat liver plasma membranes and expressed in COS-7 cells
-
FAAH mutants are expressed in the Escherichia coli strain BL21. All Escherichia coli expression constructs contained a deletion of the N-terminal transmembrane domain of FAAH. Deletion of this region facilitates its purification from Escherichia coli but has no effect on the enzymatic activity of FAAH. Some mutants are expressed mainly as inclusion body in Escherichia coli, preventing a detailed analysis of their catalytic function in this system. The expression of FAAH mutants in COS-7 cells provides a system where the majority of these variants can be directly compared
-
wild-type FAAH and FAAH protein lacking the N-terminal transmembrane domain, expression in COS-7 cells and in Escherichia coli
-
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
injury to peripheral nerves induces changes in FAAH expression pattern in dorsal root ganglion, while inflammation of peripheral tissues does not induce changes in the FAAH expression pattern, overview
-
ENGINEERING
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
A487V
-
kcat/Km for nonanoyl p-nitroanilide is 1.3fold higher than wild-type value, kcat/Km for myristoyl p-nitroanilide is 1.5fold lower than wild-type value, kcat/Km for oleoyl p-nitroanilide is 1.4fold lower than wild-type value
D167A
-
mutant enzyme shows 48% of wild-type activity with oleamide as substrate
D237E
-
mutant enzyme shows 12% of wild-type activity with oleamide as substrate
D237N
-
mutant enzyme shows 2.3% of wild-type activity with oleamide as substrate
E143Q
-
mutant enzyme shows 60% of wild-type activity with oleamide as substrate
G489A
-
kcat/Km for nonanoyl p-nitroanilide is 3fold lower than wild-type value, kcat/Km for myristoyl p-nitroanilide is 1.9fold lower than wild-type value, kcat/Km for oleoyl p-nitroanilide is 1.4fold than wild-type value
H184Q
-
activity with oleamide is similar to wild-type enzyme
H358A
-
activity with oleamide is similar to wild-type enzyme
H449A
-
activity with oleamide is similar to wild-type enzyme
I491A
-
mutant displays a greatly reduced binding affinity for medium-chain pNA substrates (7-12 carbons), kcat/Km for nonanoyl p-nitroanilide is 8.1fold lower than wild-type value, kcat/Km for myristoyl p-nitroanilide is identical to wild-type value, kcat/Km for oleoyl p-nitroanilide is 2.1fold lower than wild-type value
K142A
-
mutation abolishes the property of FAAH to degrade amides and esters with equivalent catalytic efficiencies, generating a catalytically compromised enzyme that hydrolyzes esters more than 500fold faster than amides. Mutant enzyme shows an altered pH-rate profile
K142A
-
mutation decreases the amidase activity of FAAH greater than 100fold without detectably impacting the structural integrity of the enzyme, mutant enzyme shows 3% of the oleoyl ester hydrolysis compared to wild-type enzyme
K142A
-
the greater reduction of Ser241 labelling rate in the K142A/S217A double mutant, compared to the K142A and S217A single mutants, suggests that Lys142 and Ser217 cooperate to deprotonate Ser241
K142A/R243A
-
no hydrolysis of oleoyl methyl ester
K142A/S217A
-
the greater reduction of Ser241 labelling rate in the K142A/S217A double mutant, compared to the K142A and S217A single mutants, suggests that Lys142 and Ser217 cooperate to deprotonate Ser241
K142E
-
mutant enzyme displays severely diminished catalytic activity, but one that now maintains ability of FAAG to react with amides and esters at competitive rates. Mutant enzyme shows an altered pH-rate profile
K142Q
-
mutation abolishes the property of FAAH to degrade amides and esters with equivalent catalytic efficiencies, generating a catalytically compromised enzyme that hydrolyzes esters more than 500fold faster than amides. Mutant enzyme shows an altered pH-rate profile
K255A
-
mutant enzyme shows 17% of wild-type activity with oleamide as substrate
L192F/F194Y/A377T/S435N/I491V/V495M
P97612
generation of a humanized version of the rat FAAH by replacment of six amino acids in the active site of the rat FAAH protein in order to recreate the binding profile of the human enzyme
N206A
-
mutant enzyme shows 11% of wild-type activity with oleamide as substrate
R243A
-
mutation decreases the amidase activity of FAAH greater than 100fold without detectably impacting the structural integrity of the enzyme, mutant enzyme shows 24% of the oleoyl ester hydrolysis compared to wild-type enzyme
S217A
-
mutant shows 2300fold reductions in kcat for oleamide
S217A
-
mutation decreases the amidase activity of FAAH greater than 100fold without detectably impacting the structural integrity of the enzyme, no hydrolysis of oleoyl methyl ester
S217A
-
the greater reduction of Ser241 labelling rate in the K142A/S217A double mutant, compared to the K142A and S217A single mutants, suggests that Lys142 and Ser217 cooperate to deprotonate Ser241
S217A/S218A
-
mutant displays a 230000fold decrease in kcat for oleamide
S218A
-
mutant shows 95fold reductions in kcat for oleamide
S218A
-
mutation decreases the amidase activity of FAAH greater than 100fold without detectably impacting the structural integrity of the enzyme, mutant enzyme shows 3% of the oleoyl ester hydrolysis compared to wild-type enzyme
S241A
-
mutant exhibits no detectable catalytic activity for oleamide
S241A
-
mutation decreases the amidase activity of FAAH greater than 100fold without detectably impacting the structural integrity of the enzyme, no hydrolysis of oleoyl methyl ester
T257A
-
mutant enzyme shows 65% of wild-type activity with oleamide as substrate
T488A
-
kcat/Km for nonanoyl p-nitroanilide is 2.8fold lower than wild-type value, kcat/Km for myristoyl p-nitroanilide is 1.4fold lower than wild-type value, kcat/Km for oleoyl p-nitroanilide is 1.6fold lower than wild-type value
additional information
Q7XJJ7
construction of three independent lines OE2, OE7,and OE11 overexpressing AtFAAH, and of two AtFAAH T-DNA knockouts SALK_118043and SALK_095108. AtFAAH overexpressor plants flower several days earlier than wild-type plants, and AtFAAH knockouts under both non-inductive short day and inductive long day conditions
additional information
-
FAAH-2 chimeras excluded from lipid droplets lack activity and/or are poorly expressed
additional information
-
generation of humanized rat FAAH
additional information
-
construction of FAAH-/- mice
additional information
Mus musculus C57BL/6J
-
construction of FAAH-/- mice
-
APPLICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
drug development
-
FAAH is an attractive target for treating pain
pharmacology
-
FAAH is a potential therapeutic target
medicine
-
FAAH is a promising target for the treatment of several central and peripheral nervous system disorders, such as anxiety, pain and hypertension